THE ROLE OF ARGININE METHYLATION IN MIRNA BIOGENESIS INVESTIGATED BY MS-PROTEOMICS by V. Spadotto
PhD degree in Molecular Medicine  
(Curriculum in Molecular Oncology) 
European School of Molecular Medicine (SEMM) 
University of Milan and University of Naples “Federico II” 
 
 
 
The role of arginine methylation in miRNA 
biogenesis investigated by MS-proteomics 
 
 
 
 
Valeria Spadotto 
European Institute of Oncology (IEO), Milan 
 
 
 
 
Supervisor: Dr. Tiziana Bonaldi 
European Institute of Oncology (IEO), Milan 
 
 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
My work is a game, a very serious game. 
M. C. Escher 
  
ii 
 
TABLE OF CONTENTS 
 
Figure index I 
List of abbreviations III 
1. ABSTRACT 1 
2. INTRODUCTION 2 
2.1 MicroRNA biogenesis and the Large Drosha Complex ………...................... 2 
2.2 Mechanisms of regulation of the Microprocessor……………………………… 4 
2.2.1 MicroRNA biogenesis is altered in cancer……………………………..... 5 
2.3 Protein methylation……………………………………………………………….. 6 
2.3.1 Protein Arginine Methyltransferases……………………………………… 8 
2.4 Mass spectrometry and MS-based proteomics………………………………... 10 
2.4.1 Mass spectrometry analysis in Orbitrap instruments…………………… 15 
2.4.2 Protein identification……………………………………………………….. 16 
2.5 Quantitative proteomics………………………………………………………….. 17 
2.5.1 Stable isotope labeling by amino acids in cell culture (SILAC)………... 20 
2.6 Post translational modification analysis through MS-based proteomics……. 22 
2.6.1 Classical technical approaches to study protein methylation................ 23 
2.6.2 Challenges in the MS-based analysis of protein methylation................ 24 
2.6.3 Heavy methyl SILAC for the high-confidence identification of protein 
methylation………………………………………………………………….. 
 
25 
2.6.4 MS-based discrimination between symmetric and asymmetric 
arginine di-methylation ……………………………………………………. 
 
27 
2.7 State-of-the-art on global methyl-proteomics studies………………………..... 28 
3. AIM OF THE WORK ……………………………………………………………......... 30 
4. MATERIAL AND METHODS ………………………………………………….......... 31 
4.1 Cell culture ………………………………………………………………………… 31 
4.1.1 Heavy methyl SILAC labeling of cells ……………....…………………… 31 
iii 
 
4.1.2 SILAC labeling of cells …………………………………………………..... 31 
4.2 Cell lysis and sub-cellular fractionation ………………………………………… 32 
4.3 Protein co-immunoprecipitation (co-IP) ………………………………………... 32 
4.4 In-gel digestion of immunoprecipitated proteins …………………………….. 33 
4.5 Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS)…… 34 
4.6 Assigning hmSILAC/ SILAC peptide sequences using MaxQuant and data 
analysis………………………………………………………………………...... 
 
34 
4.6.1 hmSILAC peptide assignment and data analysis ………………………. 35 
4.6.2 SILAC peptide assignment and data analysis ………………………..… 36 
4.7 Cell transduction with lentiviral vectors ………………………………………... 37 
4.8 Western Blot analysis ……………………………………………………………. 38 
4.9 Total and small- RNA extraction ………………………………………………... 39 
4.10 cDNA synthesis and real-time PCR …………………………………………... 39 
4.11 Primers used for quantitative PCR .......………………………………………. 40 
4.12 Taqman Array Human microRNAs ……………………………………………. 42 
4.13 Small-RNA sequencing: preparation of libraries, sequencing and data 
analysis …………………………………………………………………..……….. 
 
42 
5. RESULTS ……………………………………………………………………………… 43 
5.1 Characterization of the Large Drosha Complex methylation pattern………... 43 
5.1.1 Heavy methyl SILAC labeling of HeLa S3 ……………………………… 45 
5.1.2 Nuclear and cytosolic sub-cellular fractionation of HeLa S3 ………..… 46 
5.1.3 Co-immunoprecipitation of the Large Drosha Complex …………..…… 47 
5.1.4 Features of the Large Drosha Complex methyl-proteome……………... 49 
5.2 Set up of PRMT1 depletion and overexpression to modulate the Large 
Drosha Complex methylation state……………………………………..……..... 
 
51 
5.2.1 Set up of PRMT1 knock down …………………………………………... 52 
5.2.2 PRMT1 overexpression set up …………………………………………… 54 
5.3 Identification of PRMT1-specific targets on the Large Drosha Complex ..… 56 
iv 
 
5.3.1 Analysis of the effect of PRMT1 depletion on the LDC at protein and 
methyl-peptides levels……………………………………………………... 
 
56 
5.3.2 Validation of some PRMT1-specific targets on the complex through 
PRMT1 overexpression …………………..……………………………….. 
 
63 
5.4 Study of the impact of PRMT1-mediated methylation on miRNA 
biogenesis……………………………………………………………………….…. 
 
68 
5.4.1 The effect of PRMT1 depletion on the expression of miRNAs………… 68 
5.4.2 Global miRNA expression analysis …………………………………….... 71 
5.4.3 Primary and precursor miRNA analysis upon the depletion of PRMT1 75 
5.5 Investigation of the molecular mechanisms linking protein methylation to 
altered miRNA biogenesis ………………………………………………………. 
 
78 
5.5.1 Analysis of the sub-cellular localization of Large Drosha Complex 
subunits in the absence of PRMT1…………………………………........ 
 
78 
5.5.2 The role of methylation in the regulation of protein-RNA or protein-
protein interactions ……………………………………………………….. 
 
79 
5.6 Impact of other PRMTs on miRNA biogenesis ………………………………... 83 
6. DISCUSSION …………………………………………………………………..……… 87 
REFERENCES …………………………………………………………………………… 97 
APPENDIX …………………………………………………………………..…..……...... 109 
  
  
  
  
  
  
  
 
 I 
 
FIGURE INDEX 
Fig. 1 Overview of microRNA biogenesis ……………………………………………. 4 
Fig. 2 Arginine and lysine methylation ……………………………………………….. 7 
Fig. 3 Classical workflow for bottom-up MS analysis ………………………………. 11 
Fig. 4 Scheme of the electrospray ionization (ESI) process ……………………….. 13 
Fig. 5 Schematic description of a Q Exactive HF mass spectrometer ……………. 16 
Fig. 6 Common quantitative mass spectrometry workflows ……………………….. 20 
Fig. 7 Scheme of a standard SILAC experiment ……………………………………. 21 
Fig. 8 Schematic description of the heavy methyl SILAC workflow ………………. 26 
Fig. 9 Schematic description of hmSILAC data processing through an analysis 
pipeline developed in-house …………………………………………………… 
 
36 
Fig. 10 qPCR primer designed for pri-, pre- and mature miRNAs analysis ……… 41 
Fig. 11 Description of the hmSILAC/co-IP approach to characterize the LDC 
methylome ……………………………………………………………………... 
 
44 
Fig. 12 Heavy methyl SILAC labeling of HeLa S3 cells ……………………………. 46 
Fig. 13 Optimization of the co-IP protocols for the enrichment of the Large 
Drosha Complex ……………………………………………………………….. 
 
48 
Fig. 14 Features of the in vivo methyl-proteome of the Large Drosha Complex … 50 
Fig. 15 Scheme of the strategy used to deplete and overexpress PRMT1 in Hela 
cells …………………………………………………………………………….. 
 
52 
Fig. 16 PRMT1 KD set up ……………………………………………………………... 54 
Fig. 17 PRMT1 overexpression set up ……………………………………………….. 55 
Fig. 18 Description of the SILAC/co-IP „forward‟ experiment for the identification 
of PRMT1-specific target on the Large Drosha Complex ………………….. 
 
58 
Fig. 19 Quantitative proteomics to profile changes in nuclear protein levels after 
PRMT1 depletion ……………………………………………………………… 
 
59 
Fig. 20 Large Drosha Complex methyl-peptides changes upon PRMT1 depletion 60 
Fig. 21 SILAC/co-IP approach for the validation of PRMT1-specific targets on  
 II 
 
the Large Drosha Complex …………………………………………………... 64 
Fig. 22 Profiling of the Large Drosha Complex methyl-peptides changes after 
PRMT1 overexpression ………………………………………………………. 
 
67 
Fig. 23 Optimization of PRMT1 KD protocol for miRNA expression profiling ……. 70 
Fig. 24 PRMT1 depletion causes down-regulation of mature miRNA expression  71 
Fig. 25 PRMT1 depletion causes a general deregulation of mature miRNA 
expression ……………………………………………………………………... 
 
72 
Fig. 26 PRMT1 depletion causes global down-regulation of mature miRNA 
expression ………………………………………………………………………. 
 
74 
Fig. 27 The processing of primary to precursor miRNAs is impaired by PRMT1 
depletion ………………………………………………………………………… 
 
76 
Fig. 28 Pri-, pre- and mature- miRNA analysis in specific cell compartments …… 78 
Fig. 29 The absence of PRMT1 does not affect the cellular distribution of several 
subunits of the LDC …………………………………………………………… 
 
79 
Fig. 30 Analysis of the role of RNA in modulating the interactions among 
subunits of the LDC …………………………………………………………… 
 
81 
Fig. 31 Study of the role of methylation in the regulation of protein-protein 
interactions within the LDC …………………………………………………... 
 
82 
Fig. 32 Set up of the knock down of other PRMTs …………………………………. 84 
Fig. 33 qPCR analysis of miRNAs upon the KD of other PRMTs …………………. 86 
Fig. 34 Example of ambiguous methylation assignment …………………………… 91 
Appendix 1 Heavy methyl SILAC-based library of the Large Drosha Complex 
methylated sites …………………………………………………………… 
 
109 
Appendix 2 Methylated peptides identified following the depletion of PRMT1 ….. 115 
Appendix 3 Methylated peptides commonly identified upon PRMT1 depletion 
and overexpression ……………………………………………………….. 
 
120 
 
  
 III 
 
LIST OF ABBREVIATIONS 
 
3p     3 prime 
5p     5 prime 
ADMA    Asymmetric di-methylated arginine 
Arg    Arginine 
Co-IP    co-immunopurification  
Da     Dalton 
DDA    Data dependent acquisition 
DSRM    Double strand RNA binding motif 
ESI     Electrospray ionization  
FDR     False discovery rate  
Fwd    Forward experiment 
geLC-MS/MS    In-gel digestion couple to tandem mass spectrometry 
H4R3me2a   Histone H4 arginine 3 asymmetric di-methylation 
HCD    High energy Collision Dissociation 
HILIC     Hydrophilic interaction liquid chromatography 
hmSILAC  Heavy methyl stable isotope labeling by amino acids in cell 
culture 
HPLC    High pressure liquid chromatography 
IP     Immunoaffinity purification 
KD     knock down 
LC     Liquid chromatography  
LC MS/MS   Liquid chromatography and tandem MS 
LC region   Low complexity region 
LDC     Large Drosha Complex 
LFQ    Label-free quantitation 
Lys     Lysine 
m/z    Mass-to-charge ratio 
MALDI    Matrix assisted laser desorption ionization 
Met    Methionine 
miRISC   MicroRNA-induced silencing complex  
miRNA    MicroRNA 
MMA    Mono-methylated arginine 
MS    Mass spectrometry 
MS/MS   Tandem Mass spectrometry 
nLC    Nano Liquid chromatography  
Over     Overexpression 
Pfam    Protein families database  
 IV 
 
PI     Post infection 
PKMTs    Protein lysine Methyltransferases  
Pre-miRNA    Precursor microRNA  
Pri-miRNA    Primary microRNA 
PRMTs    Protein Arginine Methyltransferases  
PTM  Post translational modification 
qPCR     Quantitative polymerase chain reaction 
RBPs    RNA-binding proteins 
Rev     Reverse experiment 
RP     Reverse phase  
RRM     RNA recognition motifs 
SAM    S-Adenosyl-methionine 
SCX     Strong cation exchange 
SDMA    Symmetric di-methylated arginine  
SDS     Sodium dodecyl sulfate 
SDS-page    Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sh-RNA    Short hairpin RNA 
SILAC    Stable isotope labeling by amino acids in cell culture  
UTR     Un-translated region 
WT     Wild type 
 
 
 1 
 
1. ABSTRACT 
 
MicroRNAs (miRNAs) are short, non-coding RNA molecules that fine tune gene 
expression at the post-transcriptional level. The efficient miRNA processing is 
fundamental to maintain their correct levels in the cell. However, although microRNA 
biogenesis is a tightly controlled pathway, alterations in this process occur in different 
pathological conditions, including cancer. Hence, dissecting the molecular mechanisms 
underlying miRNA biogenesis is crucial to understand how aberrant miRNA patterns are 
generated. The processing step operated by the Large Drosha Complex (LDC), which is 
crucial and rate limiting for the production of mature miRNAs, occurs in the nucleus and it 
consists in the cleavage of the primary miRNAs (pri-miRNAs) into the precursor miRNAs 
(pre-miRNAs). In our previous MS-based analysis of the cellular methylome, we showed 
that protein methylation frequently occurs on the majority of the LDC subunits [1], 
suggesting for the first time the possibility that this post translational modification (PTM) 
could contribute to the regulation of miRNA biogenesis.  
To investigate the role of protein methylation in the regulation of the LDC, we thoroughly 
characterized the methylated sites on the subunits of the complex, thus generating the 
first comprehensive and high-confident methyl-proteome of the LDC.  
By modulating the expression of PRMT1, the predominant Protein Arginine 
Methyltransferase in mammalian cells, we analyzed how methylations change at specific 
sites of distinct LDC subunits, thus identifying novel PRMT1 substrates. The alteration of 
the LDC-methylation state upon PRMT1 depletion correlated with an impairment of the 
pri- to- pre-miRNA processing step, which resulted in the massive deregulation of mature 
miRNA expression. Although the detailed molecular mechanism remains to be fully 
deciphered, the results described in this thesis uncover a key role of arginine methylation 
in the regulation of the LDC activity and, consequently, in miRNA biogenesis.   
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2. INTRODUCTION 
 
2.1 MicroRNA biogenesis and the Large Drosha Complex 
MicroRNAs (miRNAs) are short, non-coding RNA molecules that regulate gene 
expression by targeting specific mRNAs for degradation or translational repression, thus 
influencing diverse biological processes.  
MicroRNAs are preferentially transcribed by RNA Polymerase II (RNA Pol II) into long 
primary transcripts (pri-miRNAs), which possess the characteristic 7-methyl-guanosine 
(m7G) cap at the 5‟-end, the poly-A tail at the 3‟-end [2] and stem-loop structures where 
the mature miRNA sequences are embedded. MicroRNA genes are located in diverse 
regions of the genome: the majority of miRNAs derives from introns of non-coding or 
coding transcripts, while just some of them derive from exons [3, 4].  Often, miRNA loci, 
which are in close proximity, are transcribed as a unique transcript, giving rise to 
polycistronic transcription units [5]. In fact, many miRNAs are expressed as clusters that 
range from 2 to 19 miRNAs hairpins which are usually co-transcribed. Transcription of pri-
miRNAs can be regulated positively or negatively by various transcription factors, such as 
p53 [6, 7], MYC [8] and ZEB1 and ZEB2 [9]. Moreover, epigenetic mechanisms, including 
both DNA methylation and histone modifications, also contribute to the regulation  of 
miRNA expression [4].  
In the nucleus, pri-miRNAs are cleaved by the type-III RNase enzyme Drosha to generate 
the precursor miRNAs (pre-miRNAs), which are ~60/100 nucleotides (nt) long [10]. 
Drosha cleaves the pri-miRNA hairpin 11bp far from the „basal‟ junction and 22bp away 
from the „apical‟ junction [11] (Fig. 1). Pre-miRNAs are then exported by exportin-5 
(XPO5) in the cytoplasm [12], where they are further processed by Dicer. The type-III 
RNase Dicer cleaves the pre-miRNAs close to the terminal loop sequence, producing 
small RNA duplexes about 22nt long [13]. Dicer interacts with the Argonaute proteins to 
form the miRNA-induced silencing complex (miRISC) [14]. One strand of the dsRNA is 
removed and degraded while the other (the guide strand) is retained by the miRISC and 
guides it to the recognition of complementary sequences within the 3‟ un-translated 
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regions (UTR) of target mRNAs, promoting their degradation or their translational 
inhibitions [15] (Fig. 1).  
In the multi-step event of miRNA biogenesis, the processing step operated by Drosha in 
the nucleus is crucial and rate limiting for the production of mature miRNA molecules. 
Although Drosha is the RNase effectively cleaving the RNA molecule, it requires binding 
to DiGeorge critical region 8 (DGCR8), forming the Microprocessor complex, to correctly 
interact with pri-miRNAs [16, 17]. DGCR8 binds Drosha through its C-terminus [11, 18] 
and provides additional RNA-binding recognizing the pri-miRNAs through its double 
strand RNA binding domains (dsRBDs).  Although the Microprocessor is able to cleave 
primary transcripts, there is evidence suggesting that it requires accessory proteins to be 
fully efficient [19]. Different studies identified about 20 proteins as Microprocessor 
interactors which form a larger multi-protein complex called Large Drosha Complex (LDC) 
[17, 19]. These proteins are RNA-binding proteins (RBPs) that comprise the DEAD-box 
helicases DDX5 and DDX17 (also known as p68 and p72, respectively), a number of 
heterogeneous ribonucleoproteins (hnRNPs), the FET protein family EWSR, FUS, TAF15, 
and other factors.  
The Microprocessor-associated proteins can modulate the specificity and/or activity of the 
Microprocessor and alterations in this regulation leads to aberrant miRNA biogenesis [20].  
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Fig. 1 Overview of microRNA biogenesis 
MicroRNAs are transcribed as primary miRNAs (pri-miRNAs) by RNA polymerase II (Pol 
II) in the nucleus. The long pri-miRNAs are then cleaved by the Microprocessor, which is 
composed by DROSHA and DGCR8, to produce the pre-miRNAs. The pre-miRNAs are 
exported from the nucleus to the cytoplasm by exportin 5 (XPO5) and further processed 
by the type-III RNase DICER. The mature miRNA, also known as the guide strand from 
the miRNA duplex, is loaded into the miRNA-induced silencing complex (miRISC), which 
is composed from DICER and Argonaute (AGO) proteins. miRNA directs the RISC to 
target mRNAs and mediates gene suppression by mRNA degradation and/or translational 
repression. Adapted from [21].  
 
2.2 Mechanisms of regulation of the Microprocessor 
The efficiency of pri-miRNA processing is crucial for the maintenance of appropriate 
mature miRNAs level, thus several mechanisms of regulation of the Drosha complex exist.  
One level of regulation is operated by accessory proteins within the LDC that regulate the 
efficiency of pri-miRNA processing by acting on the Microprocessor in different ways.  
For instance, DDX5 and DDX17 are required for the efficient processing of a subset of 
miRNAs by proper recruiting the Microprocessor to their pri-miRNAs [22, 23]. Moreover, 
the interaction between DDX5 and/or DDX17 with the Drosha/DGCR8 complex can be 
further regulated by several signalling pathways [24, 25].   
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Some other accessory proteins, like TARDBP, increase Drosha stability and processing 
activity through a direct protein-protein interaction [26, 27], while ILF3 and ILF2 (also 
known as NF45 and NF90, respectively) are negative regulators of miRNA biogenesis. In 
fact, they inhibit pri-let-7a and pri-miR-21 processing into pre-miRNAs by sequestering 
them from the Microprocessor [28].  
The protein levels of Drosha and DGCR8 in the cell are also tightly regulated since they 
may directly influence miRNA processing. A double-negative feedback loop ensures the 
accurate coupling of the Microprocessor proteins: on the one hand DGCR8 stabilizes 
Drosha protein level through direct interaction and, on the other, Drosha modulates the 
abundance of DGCR8 mRNA, cleaving two hairpin structure within its 5‟UTR and leading 
its mRNA to degradation [29, 30].  
Also post translational modifications (PTMs) can regulate several subunits of the complex. 
DGCR8 phosphorylation increases its stability, leading to an increase in pro-growth 
miRNA levels [31]; Drosha phosphorylation is required for its correct localization to the 
nucleus while acetylation prevents its ubiquitination and consequent degradation [32, 33]. 
In a previous study [1], we showed for the first time that protein methylation is frequently 
occurring on the LDC proteins. This observation was further confirmed by others [34] and 
points towards a role of this modification in the regulation of miRNA biogenesis. 
 
2.2.1 MicroRNA biogenesis is altered in cancer 
A number of large-scale miRNA expression profiling studies have recently shown that 
miRNAs are deregulated in different pathological conditions, including cancer [4]. 
Individual miRNAs can have either oncogenic or tumour-suppressive function, based on 
their inhibitory activity on tumour-suppressive or oncogenic targets, respectively. 
Moreover, miRNA signatures that distinguish between normal and tumoral samples have 
been identified [35, 36] and miRNA patterns of expression have shown to be useful tool to 
predict therapeutic outcomes in specific cancer types [37]. Interestingly, in the last years 
several studies showed that mature miRNAs are globally down-regulated in cancer, and 
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that this down-regulation is paralleled by the accumulation of pri-miRNAs, suggesting that 
the miRNA biogenesis might be impaired [36, 38].  
Nowadays, it is well known that miRNA biogenesis plays a central role in cancer and that 
deregulation or deficiency of the components of the processing machinery often underlies 
cancer progression [21, 39, 40]. All the aforementioned regulatory mechanisms 
(paragraph 2.2) of miRNA processing pathway can be altered in cancer, as reviewed in 
[21]. Pri-miRNAs transcription can be affected by genetic alterations, altered epigenetic 
modifications or transcription factors, while pri-miRNA processing is deregulated by 
genetic mutations or altered expression levels of both the Microprocessor and the RBPs 
involved in its processing, such as DDX5 and DDX17. Whereas alterations of Drosha and 
DGCR8 globally affect mature miRNA levels, the deregulation of the accessory proteins 
impinges on specific subset of miRNAs.  
Last, the export of the pre-miRNAs from the nucleus to the cytoplasm can also be 
affected, as well as the cytosolic processing of the precursors by Dicer and the Argonaute 
proteins.  
For these reasons, there is increasing interest and necessity in dissecting the molecular 
mechanisms underlying miRNA biogenesis.  
 
2.3 Protein methylation 
Methylation is a post translational modification occurring on a variety of nuclear and 
cytoplasmic substrates. Initially, methylation was extensively studied as a key-determinant 
of the histone code in the context of the epigenetic regulation of gene transcription. 
However, the recent discovery that methylation occurs on an increasing number of non-
histone proteins confirmed that it is implicated in every aspect of cellular biology, including 
transcription, RNA splicing, DNA repair, signal transduction and modulation of the immune 
response [34, 41-46]. Given its widespread involvement in different biological processes, 
deregulation of methylation correlates with diverse pathological conditions, such as 
neurodegenerative, cardiovascular diseases and cancer [47-50]. 
Methylation is a covalent modification that involves the addition of methyl-groups to the -
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amine of lysine (K) and to the guanidino groups of arginine (R) residues. It is catalyzed by 
a family of enzymes called protein methyltransferases, specific for either lysines (PKMTs) 
or arginines (PRMTs). Lysine can be mono-, di- or tri-methylated by PKMTs, while 
arginine can be mono- or di-methylated by PRMTs. A distinct feature of R di-methylation 
is that it can be symmetric or asymmetric, depending on the number of nitrogen atoms of 
the guanidino group involved in the reaction [50] (Fig. 2). Both PRMTs and PKMTs are S-
Adenosyl-methionine (SAM or AdoMet) – dependent and catalyze the transfer of methyl-
groups from the methyl-donor SAM to a plethora of biological targets in the cell. The 
addition of a methyl-group to an arginine or lysine residue within a protein reduces the 
hydrogen bonding potential of the K and R side chains and alters the bulkiness and 
hydrophobicity of the protein, but does not change the cationic charge of the residues. As 
a consequence, this can positively or negatively affect the interactions occurring between 
the substrate and other proteins [50, 51].  
 
 
Fig. 2 Arginine and lysine methylation 
A) Molecular structure of unmodified, mono- and di-methylated arginine. Type-I and II 
protein arginine methyltransferases catalyze asymmetric and symmetric di-methylation, 
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respectively. B) Molecular structure of unmodified, mono-, di-, and tri-methylated lysine. 
Adapted from [52].  
 
In particular, arginine is structurally unique compared to other amino acids as its 
guanidino group is positively charged and can form extended hydrogen bonding networks 
with both proteins and nucleic acids [53]. The methylation of R residues alters both the 
shape of the R side-chain and the hydrogen bonding potential of the residue. Thus, 
cellular responses to mono- and symmetric/ asymmetric di-methylation, which are specific 
to the type of modification, all appear to be mediated by alteration in protein-protein, 
protein-RNA and protein-DNA interactions [41, 46].  
For many years methylation was considered a stable and irreversible modification, but the 
reversal of lysine methylation is now well established thanks to the identification of two 
families of histone KDMs, which both act through the oxidation of the methyl-groups [54, 
55]. In contrast to lysine methylation, the existence of arginine demethylases is still 
controversial. In fact, although the 2-oxoglutarate-dependent JMJD6 has been reported to 
catalyze methyl-arginine demethylation of histone and non-histone substrates [56] [57], 
the biochemical evidence for its activity is still not unequivocal [57, 58].  
 
2.3.1 Protein Arginine methyltransferases 
In mammals, arginine methylation is catalyzed by a family of nine members, called Protein 
Arginine Methyltransferases (PRMTs). All PRMTs have a highly conserved 
methyltransferase domain, while they contain a unique N-terminal region which varies in 
length and that can be responsible for substrates recognition and enzymatic activity 
regulation [46]. They can be classified according to the type of modification they catalyze: 
type-I enzymes catalyze the formation of mono-methylated arginine (MMA) and 
asymmetric di-methylated arginine (ADMA) (and include PRMT1, PRMT2, PRMT3, 
PRMT4, PRMT6 and PRMT8), type-II enzymes are responsible for MMA and symmetric 
di-methylated arginine (SDMA) (and comprise PRMT5 and PRMT9) and the type-III 
enzyme PRMT7 deposits only mono-methylation [41].  
PRMT1 is the major type-I methyltransferases in mammalian cells and is responsible for 
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the 85% of the ADMA [59]. On histones, PRMT1 methylates histone H4 at arginine 3, 
generating the H4R3me2a mark [60], which is associated with transcriptional activation. In 
fact, this modification allows the recruitment of methyl-binding proteins and the deposition 
of other active PTM marks in the proximity [61]. Although several studies report that 
PRMT1methylates preferentially R located within arginine-glycine (RG) motifs, a recent 
evidence suggest that PRMT enzymes target arginine residues located in RG and non-RG 
sequence motifs with similar preference [34]. The PRMT1 gene can produce seven 
isoforms (PRMT1v1-v7) through complex alternative splicing in the 5‟-end of its pre-
mRNA. The isoforms differ in their N-terminal sequences and in their molecular weight; 
moreover, they have different enzymatic activity, substrate specificity, sub-cellular 
localization and interactions [62, 63]. Several studies have shown that PRMT1 is 
overexpressed in diverse types of cancer and that in human breast cancer cells and 
tumour tissues it is possible to observe an unbalance among distinct PRMT1 splicing 
variants, suggesting that these isoforms might be functionally different, especially in 
disease [64].  
PRMT2 and PRMT3 are type-I PRMT that exhibits high sequence homology with the 
catalytic domain of PRMT1 [65]. The former has weak methyltransferase activity 
compared to PRMT1 [66] and, with the exception of H3R8 [67], specific substrates have 
not been identified yet. However, it has been shown to interact with estrogen and 
progesterone receptors in a ligand-dependent manner enhancing their activity [68]. The 
latter, methylates the ribosomal protein RPS2, thus regulating ribosome homeostasis, and 
p53 acting in a complex with ARF and VHL [69, 70], 
PRMT4, also known as CARM1 (co-activator associated arginine methyltransferase 1) 
due to its role of transcriptional co-activator, is a type-I enzyme that methylates several 
histone and non-histone proteins. The recruitment of CARM1 to transcriptional promoters 
results in the methylation of histone H3 at R17 and R26 (H3R17me2a, H3R26me2a), 
marks associated to transcriptional activation [41, 71, 72].  
PRMT5 is the major type-II PRMT in mammalian cells and exerts its activity both in the 
nucleus and in the cytoplasm. In the nucleus, it acts like a strong transcriptional repressor, 
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while in the cytoplasm it is involved in snRNP (Small Nuclear Ribonucleoproteins) 
biogenesis [73] and is a key regulator of the core splicing machinery [74]. 
PRMT6 is a nuclear type-I PRMT with a similar structure and preference for RG motifs 
compared to PRMT1 [75]. Its primary targets are histone H3, on which it produces the 
repressive mark H3R2me2a [76, 77], and DNA polymerase [78]Although its primary 
function is transcriptional repression, in some instances it has also been shown to act as a 
co-activator [79, 80].  
PRMT7 activity is still controversial. In fact, it has been described to have type-III activity 
towards some substrates and type-II towards others, suggesting that distinct substrates 
might be methylated in different fashions by this enzyme [81, 82].  
PRMT8 is a unique member of the PRMTs family since it is expressed only in the brain 
and is localized solely to the plasma membrane via myristoylation of its N-terminus [83]. 
Recently, it was reported that PRMT8 is involved in the pathogenesis of amyotrophic 
lateral sclerosis and that it plays critical roles in neural development [84, 85].  
PRMT9, together with PRMT5, belongs to the type-II class of PRMTs. In fact it 
symmetrically methylates the spliceosome-associated protein SAP145, a component of 
the U2 snRNP that plays a critical role in the early stages of splicing [86].  
 
2.4 Mass spectrometry and MS-based proteomics 
In the last decade, technological improvements produced mass spectrometers 
characterized by progressively higher resolution, sensitivity and performance. Nowadays, 
the most widely used analytical setup for shotgun proteomic analysis is the liquid-
chromatography coupled with tandem mass spectrometry (LC-MS/MS). The classical 
workflow for the identification and characterization of proteins from a complex mixture is 
the “bottom-up” approach, illustrated in Fig. 3, in which proteins are eventually separated 
and then digested with proteases into peptides prior to Mass Spectrometry (MS). The 
most common protease used in proteomic analyses is trypsin, which cleaves at the C-
terminus of lysine and arginine residues unless they are followed by a proline residue. 
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Trypsin is commonly used in proteomics because its cleavage produces peptides about 
10-12 amino acids long, which are easily detectable by MS.  
In order to decrease the complexity of the mixture, peptides are then separated by nano-
liquid chromatography -typically in reversed phase mode (RP-nLC)- which separates them 
according to their hydrophobicity. In RP-LC the polar and volatile mobile phase favors the 
ion transferring into the mass analyzer of the mass spectrometer, which measures the 
mass-to-charge ratio (m/z) of the peptide ions. In the mass spectrometer precursor 
peptides are isolated and scanned (full scan MS, MS or MS1) to identify the m/z that 
provides information on the elemental composition of the peptide. The most intense 
precursors are then fragmented into the constituent fragment ions through MS/MS events 
(tandem MS or MS2), to recover their amino acid sequence. Peptide identification is 
achieved by comparing the experimental MS/MS spectra derived from peptide 
fragmentation with theoretical MS/MS spectra generated by in silico digestion of a protein 
database. Protein identification is then inferred by assigning peptide sequences to 
proteins.  
 
Fig. 3 Classical workflow for bottom-up MS analysis 
A protein mixture from a biological sample is separated by SDS–PAGE and enzymatically 
digested into peptides, which are then separated by High-performance Liquid 
Chromatography (HPLC). Peptides are then ionized and analysed by tandem mass 
spectrometry, generating MS and MS/MS spectra, respectively. MS/MS spectra are 
searched against protein databases to obtain the protein identification. Adapted from 
www.biochem.mpg.de 
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A mass spectrometer consists of three main parts: 
1. The ion source that converts the peptides into gas-phase ions. 
2. The mass analyzer, which separates the ions according to their m/z. 
3. The detector that records the number of ions at each m/z value. 
1. Ion Source and ionization of peptides  
Mass spectrometers can measure m/z values of ionized molecules in gas-phase. 
However, since proteins and peptides are non-volatile and polar molecules, they require 
an ionization method that transfers them into the gas-phase, for the subsequent analysis. 
One of the most important innovations in this type of instruments was the introduction of 
“soft-ionization” technologies, which allows the ionization of proteins and peptides without 
causing extensive degradation. Two techniques are commonly used: matrix-assisted laser 
desorption ionization (MALDI) [87, 88] and electrospray ionization (ESI) [89]. In a MALDI 
source, peptides are co-crystallized with a solid-phase matrix on a metal plate. The matrix 
typically consists of a small organic molecule such as -cyano-4-hydroxycinnamic acid 
and di-hydroxy benzoic acid (DHB). When laser pulses irradiate the resulting solid 
mixture, this absorbs the laser energy and transfers it to the acidified peptides. At the 
same time, the rapid heating causes desorption of both matrix and newly formed [M+H] 
+ 
protonated peptides into the gas-phase. MALDI ionization can support different types of 
mass analyzers, but the most common combination for proteomics studies is the 
MALDI/time-of-flight (TOF) setup [90].  
Unlike MALDI, ESI source produces ions from a solution. Peptides exist as ions in solution 
because they contain functional groups whose ionization is controlled by the pH of the 
solution. At acidic pH values, protonation of the amines confers overall positive charge to 
peptides, while at basic pH, de-protonation of the amines and carboxyl groups confers an 
overall negative charge. Fragmentation of peptide ions is favoured by positive charges on 
the peptide ions. For these reasons, ESI of peptides is most commonly done in the 
positive ion mode to analyse acidic samples. Briefly, the ESI process consists of the 
formation of an electrically charged spray driven by the application of a high voltage (2–6 
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kV) between the end of the LC-column and the inlet of the mass spectrometer. The 
electrically charged spray drives the desolvation of peptide-solvent droplets. The high 
temperature provided by a heated capillary and the sheath gas flow at the mass 
spectrometer inlet help this process (Fig. 4). ESI sources are typically combined with 
reverse phase high-pressure liquid chromatography (RP-HPLC), which allows the 
separation of very complex peptide mixtures prior to MS analysis. An important 
implementation in ESI includes the micro and nano-ESI sources where the flow rates of 
the analytes are lowered to micro and nanoliter/min, respectively, improving the sensitivity 
[91, 92].  
 
 
 
Fig. 4 Scheme of the electrospray ionization (ESI) process 
Peptides eluted from the chromatographic column are ionized by a high voltage applied 
between the capillary and the mass spectrometer. Charged liquid forms a cone shape 
(known as the Taylor cone) and the analyte-solvent droplets burst away into a spray. 
Adapted from http://www.lamondlab.com.  
 
2. Mass analyzer and dissociation methods  
The mass analyzer is the core of the mass spectrometer and its key function is the 
storage and separation of ions based on their m/z. Common mass analyzers for peptide 
 14 
 
analysis from complex mixture are: the linear ion trap (LIT), the Orbitrap, the FT-ICR, the 
quadrupole (Q) and the above-mentioned TOF. Although these mass analyzers differ in 
the details of how they work, they all select a single m/z species from a mixture of peptide 
ions (generated by the source) and fragment them producing the MS/MS spectrum. This 
enables extrapolating the primary sequence of the peptide of interest and inferring the 
presence and position of post translational modifications.  
Various fragmentation techniques can be employed. In the collision-induced dissociation 
(CID) and higher energy collision dissociation (HCD) methods gas-phase protonated 
peptides/proteins are subjected to multiple collisions with rare gas atoms, resulting in the 
breakage of the peptide backbone at -CO-NH- bonds [93] and to the formation of the 
characteristic b- and y-ions (at N- and C-terminus, respectively) which are used for the 
univocal peptide identification. This type of fragmentation increases the frequency of 
relevant modification-specific fragmentation events in high resolution MS/MS spectra and 
is therefore suitable for the analysis of PTMs in bottom-up experiments [94].  These 
methods generate limited information for peptides longer than 15 amino acids, therefore 
Electron capture dissociation (ECD) and electron transfer dissociation (ETD) can be used. 
These approaches induce fragmentation of the peptide backbone based on gas-phase 
reactions using either thermal electrons or formation of radical ions, respectively, and are 
particularly suitable for sequencing longer peptides or whole proteins [95].  
In a typical shotgun proteomics workflow, peptides are analysed in a data-dependent 
acquisition mode (DDA), in which the mass analyzer selects the most intense ions in a 
certain time window and subject them to fragmentation. Then the analyzer automatically 
switches back to the full scan MS mode and selects the next most intense ions to be 
fragmented. Hence, DDA is biased towards the most abundant species.  
3. Detector  
The detector is located at the end of mass spectrometer and records the number of ions 
at each m/z value. Most often, the detectors are electron multipliers or micro-channel 
plates, which emit a cascade of electrons when each ion hits the detector plate [96]. This 
cascade results in the amplification of each ion hit, to improve sensitivity. This process is 
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performed under vacuum to remove gas molecules and contaminating non-sample ions, 
which can collide with sample ions and produce non-specific reaction products.  
 
2.4.1 Mass spectrometry analysis in Orbitrap instruments 
In the last years mass spectrometers have continuously improved in terms of sensitivity, 
speed, mass accuracy and resolution. In particular, Orbitrap mass analyzer 
advancements have made the mass spectrometers based on this tool the instruments of 
choice for shotgun proteomics. The Orbitrap mass analyzer consists of a coaxial central 
spindle electrode surrounded by a barrel-like electrode [97]. The Orbitrap traps ions in an 
electric field and causes them to orbit and oscillate around a central electrode in ring 
shapes. The oscillation frequency along the electrode depends on the m/z. The detector 
picks up the axial motion of the ions and this measure is Fourier-transformed to yield high- 
resolution mass spectra [98].  
The experiments reported in this thesis were performed on a Q Exactive HF Orbitrap MS 
operating in DDA mode (see previous paragraph) (Fig. 5). Briefly, the ions generated in 
the ESI source are injected into the mass spectrometer and enter the S-lens. The S-lens 
focuses the ion beam before they pass through the Advanced Active Beam Guide 
(AABG). Here, the path is bent of 90° resulting in the removal of many 
uncharged/contaminants before entering the Quadrupole. In the Quadrupole the most 
abundant ions are selected and let into the C-trap to be then guided to the Orbitrap where 
MS1 are acquired. While they are transferred to the HCD cell to be fragmented, the 
following package of ions is already entered in to the C-trap, to start a new MS-MS/MS 
cycle. The fragment ions generated in to HCD cell are sent back into the Orbitrap analyzer 
where also the MS/MS spectra are detected at high resolution.  
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Fig. 5 Schematic description of a Q Exactive HF mass spectrometer  
(Adapted from www.thermofisher.com) 
 
2.4.2 Protein identification 
After acquisition, data are interpreted by mapping the MS/MS spectra back to the peptide 
that was subjected to fragmentation.  Several algorithms have been developed to analyze 
MS/MS spectra, but they all follow a similar rationale. Briefly, every MS/MS ion spectrum 
is searched against a database containing all the theoretical fragmentation patterns 
constructed for the peptides of the searched database. User-defined criteria, like the mass 
tolerance, the proteolytic enzyme used and the presence of fixed and variable 
modifications, restrict the pool of candidate peptides. The output of the search is a list of 
fragment ion spectra matched to the peptide sequence, ranked according to the search 
score. The score measures the similarity between the experimental spectrum and the 
theoretical one, and allows discriminating true and false identifications. To estimate the 
false discovery rate (FDR) one of the most common approaches is the target-decoy 
search [99], in which MS/MS spectra are searched against a target database of protein 
sequences augmented with the reversed sequences of the same database. Once 
established an FDR threshold, this is used to filter the data and remove false positive 
peptide identifications. Different analysis programs are available, such as Andromeda 
within the MaxQuant suite [100], MASCOT [101] and SEQUEST [102].  
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2.5 Quantitative proteomics 
In the last few years, following the diffusion of mass spectrometry-based techniques, it 
has become evident that the qualitative identification of proteins is not sufficient for 
comparative analyses of functional states, and that quantitative data are much more 
informative to characterize a certain model system. However, mass spectrometry is not a 
quantitative technique per se, as a consequence of different facts. First, the ion intensity is 
proportional to its amount but it is also dependent on the chemical-physical properties of 
the corresponding peptide, such as the molecular composition, the charge and the 
hydrophobicity. Second, the comparative analysis between two different LC-MS/MS runs 
is influenced by external variations like the temperature and the chromatography 
reproducibility. Third, in data dependent acquisition (DDA) methods the choice of the 
precursor ion to be fragmented is stochastic and depends mostly on its abundance, thus 
limiting the possibility of profiling a sample completely and restraining the robust detection 
of low abundance peptides.  
In order to overcome these limitations, different strategies have been developed and can 
be divided into two groups:  label-free quantitation (LFQ) strategies, that are employed to 
compare the amount of proteins in different LC-MS runs without requiring particular 
sample handlings, and strategies based on isotope labeling, which require a specific 
preparation of the sample prior to LC-MS analysis (Fig. 6). 
Label-free strategies take advantage of peptide intrinsic characteristics and the 
quantification is made post-acquisition. These approaches can be grouped in: 1) intensity-
based strategies, where the quantification relies on the comparison of one or more 
peptide intensities of the same protein in different samples and 2) spectra counting 
quantification strategies, based on the number of MS/MS spectra for the same protein in 
different samples.  
In the former approaches, the ion chromatograms for every peptide are extracted from a 
LC-MS/MS run and their mass spectrometric peak areas are integrated over the 
chromatographic time scale (Extracted ion chromatogram, XIC or area under the curve, 
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AUC). These strategies rely on the concept that the XIC for a given peptide is linearly 
correlated with its abundance. XICs of the same peptide in different samples are extracted 
and compared for the peptide quantification. Thus, these approaches require extremely 
reproducible chromatography among multiple runs and ad hoc software capable to 
perform retention time realignment and peptide intensity normalization over the global 
intensity.  Spectral counting strategies are based on the rationale that the abundance of a 
protein correlates linearly with the number of MS/MS spectra produced for its peptides. 
Thus, relative quantitation is achieved by comparing the number of such spectra between 
a set of experiments [103, 104]. Limits of spectral counting approaches are that physical 
and chemical properties of peptides influence this linear correlation and that accurate 
protein quantification requires the acquisition of a high number of spectra. 
Label-free strategies offer the great advantage that can be extended to a theoretically 
infinite number of conditions and can be applied to every type of samples (cell lines, 
primary cells, tissues, etc.). However, LFQ requires highest technical and experimental 
reproducibility and leads to an overall lower accuracy in protein quantification in respect to 
isotope-based techniques. 
Isotope-base quantitation methods are all based on the same rationale: creating a mass 
shift that distinguishes peptides deriving from different samples within a single MS 
analysis. Generally, samples from different biological conditions are isotopically light- (L) 
or heavy- (H) labeled and then mixed in equal amounts. The signals deriving from the two 
samples can be distinguished due to a known mass shift between L and H peptides. Thus, 
the H/L intensity ratio allows the accurate quantification of the relative amounts of 
peptides and proteins originally present in the two samples. The isotope can be 
introduced in the peptides at different stages during the sample processing, depending on 
the labeling approach (Fig. 6), but the general rule is that the earlier this step is 
performed, the less are the variations introduced between the samples, thus the more 
accurate the quantification is. Depending on how proteins or peptides are labeled, 
isotope-based approaches can be divided into metabolic- and chemical- labeling 
strategies.  
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In the metabolic labeling, the isotope is added to growing cells as a metabolic precursor in 
order to be incorporated in the proteome during protein biosynthesis. These approaches 
are advantageous because they can be applied to in vivo studies and the samples mixing 
is carried out at the beginning of the workflow, thus minimizing the introduction of 
processing errors. For this reason, metabolic labeling approaches are compatible with 
complex purification procedures and allow accurate protein quantitation.  
In chemical-labeling strategies, the tag is added covalently to the reactive side chains of 
amino acids either before or after the proteolytic cleavage through a chemical reaction. 
The most common methods for chemical labelling are: isotope coded affinity tagging 
(ICAT)[105] and isobaric tags for relative and absolute quantitation (iTRAQ) [106]. In 
ICAT, proteins are labeled with a chemical reagent that consists of a thio-reactive group 
that labels cysteines, an isotopic linker region displaying a known mass difference, and an 
affinity biotin tag. However, the main limit of this approach is that only cysteine-containing 
proteins can be labeled and quantified at MS level. In iTRAQ, side chains of lysine 
residues are labeled with an isobaric tag that allows the quantification at MS/MS level. 
The advantage of iTRAQ is the possibility of multiplexing, by using up to 8 different 
isobaric tags. However, the efficiency of the labeling is variable and depends on sample 
complexity. Moreover, this method allows less accurate protein quantification due to the 
rather late step of labeling in the sample processing workflow. 
 
 20 
 
 
 
Fig. 6 Common quantitative mass spectrometry workflows  
Boxes in blue and yellow represent two experimental conditions. Horizontal lines indicate 
when samples are combined. Dashed lines indicate points in which experimental variation 
and thus quantification error can occur. Adapted from [103].  
 
2.5.1 Stable Isotope labeling by amino acids in cell culture (SILAC) 
The most successful example of metabolic labeling strategies is the Stable isotope 
labeling by amino acids in cell culture (SILAC), introduced by Mann and co-workers in 
2002 [107]. SILAC is a powerful and accurate procedure based on the use of essential 
amino acids where the naturally isotopes 12C, 1H and 14N (or light, L) are substituted with 
heavy (or H) isotopes (13C, 2H and 15N, respectively). In a classical SILAC experiment, two 
cell populations, representative of two different functional states, are grown in media 
containing either light or heavy isotope-coded essential amino acids for a sufficient 
number of cell doublings in order to ensure the full incorporation of the isotopes in the 
newly synthesized proteins. After complete labeling, cells grown in the two conditions will 
have two identical proteomes that only differ in protein isotope composition. Upon MS 
analysis, every peptide will be represented as a pair where the  mass is dependent on 
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both the number and the type of amino acids incorporated in the sequence [107] (Fig. 7). 
In a standard SILAC experiment cells are usually labeled with H and L arginine and lysine, 
which in combination with trypsin digestion, ensure that all peptides of a protein (except 
the C-terminal one) carry one labeled amino acid.  
 
 
 
Fig. 7 Scheme of a standard SILAC experiment 
SILAC experiment is composed of two different phases: in the adaptation phase (left 
panel), cells are grown in medium containing either light- or heavy-isotope coded amino 
acids until full incorporation (red asterisk). In the experimental phase (right panel) the two 
population are mixed, proteins are purified, digested and analysed by MS. Adapted from 
[108]. 
 
The SILAC labeling has been successfully applied to a wide variety of studies: from 
protein expression profiling to global PTM analysis, protein-protein and DNA-protein 
interaction analysis [109-112].  
In the last years, the SILAC approach has been implemented and applied to a variety of 
proteomics workflows, as reviewed in [113]. It is now possible to quantify three and up to 
five cell states in a single run [114, 115] or to quantitatively profile protein translation 
dynamics with the pulse SILAC (pSILAC) [116]. Another development of SILAC is the 
super-SILAC, which allow quantifying proteins from animal or human tissues [117]. SILAC 
labeling can also be used to directly label PTMs, as in the Heavy Methyl SILAC 
(hmSILAC) approach, developed in the group of Mann in 2004 [118] (see paragraph 
2.6.3). 
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2.6 Post translational modification analysis through MS-based proteomics 
The identification of a post translational modification (PTM) by MS relies on the detection 
of a mass difference (Δ mass) introduced by the modification compared to the mass of the 
unmodified peptide. Generally, the workflow used for protein identification is also 
applicable to PTM studies, although this analysis is more complex due to three main 
features of modifications. First, they are substoichiometric and therefore their analysis 
requires enrichment steps and high sensitivity of detection. Second, the covalent bond 
between the PTM and the amino acid side chain of the peptide can be labile (as for 
phosphorylation), thus it is difficult to maintain the peptide in its modified form during 
sample preparation and ionization. Third, some PTMs are highly dynamic and thus the 
enzymes responsible for removing the PTM of interest need to be inactivated.  
Given the sub-stoichiometric nature of PTMs, several strategies have been developed to 
enrich the modified peptides compared to the unmodified proteins or peptides. Examples 
of these approaches are immunopurification (IP), immobilized metal affinity 
chromatography (IMAC), titanium dioxide (TiO2) metal-based chromatography, ion 
exchange (strong cation/anion exchange, SCX/SAX) chromatography and hydrophilic 
interaction liquid chromatography (HILIC) [119]. Immunopurification relies on the use of 
antibodies able to specifically recognize a certain modification. SCX and SAX are 
separation strategies orthogonal to the reversed phase and are used to decrease the 
complexity of highly complex samples [120]. IMAC, TiO2 and HILIC are widely used in 
phosphoproteomics studies and are based on the principle that Fe3+ or TiO2
+ chelate the 
phosphate group of phosphopeptides [121-123]. However, efficient enrichment strategies 
for many PTMs are still lacking [119]. Moreover, the starting amount of material required 
for modified peptides enrichment is sensibly larger than the one typically needed for 
proteome analysis.  
In MS-based PTMs analysis, it is essential to generate enough peptide fragmentation 
information (MS/MS) for the high-confidence sequence identification and site localization 
of the modifications. Recently, the development of new instrumentation provided both high 
resolution and high mass measurement accuracies simultaneously at the MS and MS/MS 
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level, also thanks to the implementation of various fragmentation strategies (see 
paragraph 2.4). This has increased the reliability and efficiency of PTM identification and 
site-assignment [124]. In addition, to overcome the problems related with ambiguous PTM 
assignments, a number of algorithms, such as the PTM score [125], have been developed 
to statistically assess the location of a PTM on a peptide. However, despite their 
successful application in the context of phosphorylation analyses, such algorithms have 
not been optimized for the localization of other PTMs [126].    
A final issue related to PTM identification by MS is the challenge in the database search, 
which implies the search of all potential combinations of mass shifts produced by the 
modifications for each identified peptide from a protein database, thus expanding 
exponentially the search space, with effects on site-assignment confidence and FDRs. 
 
2.6.1 Classical technical approaches to study protein methylation 
PRMTs are up-regulated in various types of cancer [127] and the consequent aberrant 
methylation of critical effectors and pathways involved in the development and 
progression of cancer has been described [64]. Nowadays it is well accepted that protein 
methylation plays a fundamental role in cellular biology, both in physiological and 
pathological conditions. Hence, the study of methylation and its targets has gained 
interested and a wide range of analytical approaches has been developed.  
Classical approaches include in vitro radioactive labeling experiment using tritiated SAM 
as a methyl-donor. However, the limit of this approach is that it does not allow the specific 
assignment of the methylated sites within a protein. To address this issue, several 
antibodies that recognize modified residues and the different degree of modification have 
been developed, but the small size of the methyl-groups makes the production of such 
specific antibodies highly challenging.  
However, these methods can be used only with single proteins, are often unspecific and 
require prior knowledge of the modifications [128].  
Recently, mass spectrometry-based approaches have emerged as an extremely powerful 
analytical strategy for global investigation of protein PTMs, including methylation, due to 
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the intrinsic possibility of pinpointing different marks on distinct residues and of assessing 
quantitatively their abundances [129].  
 
2.6.2 Challenges in the MS-based analysis of protein methylation 
Although MS-based approaches have proven to be the most powerful strategy available 
for the global analysis of protein methylation, this approach remains very challenging, due 
to a number of issues.  
1. As discussed in the previous paragraph, post translationally modified peptides are sub-
stoichiometric and have to be enriched prior to MS analysis. However, in the case of 
methylated proteins/peptides the development of highly efficient pan-methyl antibodies 
has been difficult, due to the structural heterogeneity introduced by the addition of multiple 
methyl-groups [130]. Moreover, pan-methyl antibodies recognizing methylated motifs are 
likely not totally “unbiased” as they may recognize a subset of substrates in a context-
specific manner [131]. Only recently, efficient antibodies against methylated arginine and 
lysine have been produced and successfully applied to study protein methylation [132, 
133].  
2. Several amino acids substitutions are isobaric to methylation. In fact, some amino acids 
have a chemical structure that differs by a mass difference of 14 Da and are therefore 
difficult to distinguish from mono-methylation. For instance, a peptide bearing glycine and 
methylated arginine would be identical to the same peptide with a glycine-to-alanine 
substitution [118].  
3. In vitro artifacts introduced during sample preparation can be wrongly assigned as 
methylations. For instance, methanol induces the formation of mono-methylation on 
glutamic and aspartic acid residues, leading to the incorrect identification of arginine 
methylation sites during database searches [134, 135].  
4. The large number and type of mass modifications resulting from the different degrees of 
this PTM (mono-, di- and tri-methylated lysine and mono- and di-methylated arginine) may 
lead to false positive assignments, due to the combinatorial increase of possible peptide 
matches during the database searching [118].  
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For all these reasons, the identification of methylated sites by mass spectrometry can 
produce a very high number of false positives. When studying PTMs the standard method 
to control false positive peptide identifications is the application of the target-decoy 
approach (see paragraph 2.4.2), which allow to estimate FDRs. Unlike for other 
modification types, recent works from the groups of Acuto and Wilkins showed that the 
use of this strategy for methyl-peptides identification is not efficient and need to be tailored 
for this specific PTM [44, 136]. 
 
2.6.3 Heavy methyl SILAC for the high-confidence identification of protein 
methylation 
Heavy methyl SILAC (hmSILAC) is the first quantitative labeling approach that exploits 
metabolic labeling to investigate protein methylation. It is a variant of the classical SILAC 
where cells are grown in medium supplemented with either normal (light) or „heavy‟ 
methionine. Heavy methionine contains a methyl-group with one carbon-13 and three 
deuterium atoms. Cells metabolically convert the [13C3]-methionine into [
13C3]-AdoMet, 
which is the sole methyl donor in the cell. The heavy methionine is therefore incorporated 
into the backbone of newly synthesized proteins and, in addition, the heavy methyl-group 
is transferred by KMTs and PRMTs from SAM to their substrates, resulting in the heavy 
labeling of all methylations on proteins (Fig. 8A). The workflow of an hmSILAC 
experiment is identical to a conventional SILAC experiment, allowing the identification and 
quantification of methylated peptides. For each methyl-group added, hmSILAC increases 
the mass of modified peptides by 4 Da in the case of mono-methylation, 8 Da for di-
methylation and 12 Da for tri-methylation (Fig. 8B).  
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Fig. 8 Schematic description of the heavy methyl SILAC workflow 
A) [13C3]-methionine (heavy) is metabolically converted into heavy S-adenosyl-methionine 
(SAM) in the cell. Through enzymatic reactions by KMTs and PRMTs, labeled methyl- 
groups are transferred onto methylated proteins. B) Upon mixing of the light (Met0) and 
heavy (Met4) labeled cells in equal amount (1:1) and MS analysis, the type of methylated 
residue can be identified on the basis of the mass separation of the peptide pair (4 Da = 
mono-methylation, 8 Da = di-methylation, 12 Da = tri-methylation). Adapted from [118].  
 
Heavy methyl SILAC is the method of choice to study protein methylation because the tag 
is encoded in the methyl-groups itself, producing a modification-specific mass separation 
between light and heavy peptides [137]. Indeed, this increases the confidence in the MS-
based identification of methyl-peptides, because the presence of the heavy and light pairs 
is used to distinguish in vivo methylation from potential false positives that are frequent in 
methylation analyses (as described in paragraph 2.6.2). Recent studies showed that the 
direct labeling of the PTM helps to reduce the methyl-peptides FDR [136] and strongly 
support the choice of hmSILAC to study protein methylation.  
An issue of methylation analyses by MS is the multiplicity of methylation states. In 
addition, the number of modifications increases significantly with the hmSILAC, since the 
heavy version of all possible R and K methylation states is introduced in the search, 
together with the light counterpart, as variable modification. This substantially complicates 
the analysis of the data. At present, automated software for the analysis of hmSILAC data 
is not available. Software developed for the analysis of standard SILAC data, such as 
MaxQuant, can be adapted to search for heavy-methylation whereby light and heavy 
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labeled modifications are searched separately. However MaxQuant cannot be tailored to 
identify and match hmSILAC peptide pairs. For this reason, MaxQuant output files are 
integrated post-search using additional in house developed scripts to match 
corresponding light and heavy methylated peptides. Our group, as well as others, have 
contributed to the development of such analytical tools [1, 136], essential to handle large 
scale hmSILAC analysis of protein methylation.  
Another potential drawback of hmSILAC is that it does not allow discriminating between 
methylated and methionine-containing peptides, since the heavy methionine is also 
incorporated into the backbone of the peptides. However, labeling strategies to bypass 
this issue are available, such as the isomethionine methyl SILAC (iMethyl-SILAC) [44]. In 
this approach the light methionine is substituted with the isomethionine (methionine-13C4). 
The two stable isotope-labeled methionines are nearly isobaric but differ in the distribution 
of the additional mass. The methyl-groups transferred during methylation are still light or 
heavy, but methionine incorporated during protein synthesis are nearly isobaric and as a 
result, i-methyl SILAC doublets will only arise from methylated peptides [44]. 
 
2.6.4 MS-based discrimination between symmetric and asymmetric arginine di-
methylation 
Symmetric and asymmetric di-methylation of arginine residues are isomeric modifications 
that have proven to have distinct biological effects [61]. Moreover, the evidence of the 
increase of symmetric di-methylation after loss of PRMT1 [138] or upon inhibition of type- I 
PRMTs [139] suggest the possibility that type-II enzymes may compensate or scavenge 
the loss of asymmetric di-methylation. This evidence highlights the importance of 
discriminating between the two types of di-methylated arginine residues. Although the 
majority of studies used selective antibodies capable of distinguishing between SDMA and 
ADMA, MS can also be employed for this purpose. Several studies indicate that, upon 
MS/MS fragmentation, differentially methylated peptides generate “diagnostic ions” that 
can be used to identify the distinct type of dimethyl-arginine decorating the peptide. In 
particular, the presence of the characteristic methyl-guanidine group ion was used to 
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increase the confidence of methyl-site assignment, in specific dissociation conditions and 
in a hmSILAC setup [118, 140, 141]. However, the systematic use of diagnostic fragment 
ions in global methylation analyses has not yet been explored systematically.  
 
2.7 State-of-the-art on global methyl-proteomics studies 
In the last decade several groups exploited MS-based approaches to perform global 
analysis of protein methylation with the aim of characterizing the cellular methyl-proteome. 
Different strategies of biochemical enrichment and fractionation methods prior to MS 
analysis have been used to increase the identification of methylated sites.  
In 2003, Boisvert and colleagues conducted one of the first global analyses of methylation 
combining MS with antibody-based enrichment of asymmetrically and symmetrically R-
methylated proteins. The authors reported over 200 proteins containing putative 
methylations but they were not able to specifically assign the methylation site [142]. 
Following this work, Ong and Mann introduced for the first time the hmSILAC strategy, 
which was used in combination with antibody-based enrichment to identify 59 high- 
confidence in vivo methylated sites [118]. Subsequent works from several groups, 
including ours, successfully applied the hmSILAC in global methylation studies. Heavy 
methyl SILAC was used in combination with different types of biochemical techniques to 
enrich methylated peptides based on their chemical properties, prior to the identification 
by LC-MS/MS [1, 143]. SCX, HILIC and isoelectric focusing were used, as well as SDS-
page protein separation and antibody-based enrichments of methylated proteins, leading 
to the identification of up to 400 high-confidence in vivo methyl-sites.  
In the last three years, the introduction of specific and efficient antibodies against mono- 
and asymmetrically di-methylated arginine set the basis for the development of protocols 
for the enrichment of methylated peptides instead of proteins, which have been 
successfully applied in combination with biochemical fractionation methods and MS 
analysis [132, 144]. These studies contributed to enlarge the knowledge on the methyl-
proteome, with the identification of thousands of novel methyl-sites. The application of this 
new and successful experimental strategy, combined with SILAC, allows also studying R-
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methylation dynamics following different stimulus. The group of Nielsen recently quantified 
methylation changes during transcriptional arrest [144] and after the depletion/inhibition of 
specific PRMTs [34], while Geoghegan and colleagues demonstrated that T cell activation 
induces global changes in R-methylation [44]. These works confirmed on a large scale 
that methylation is a dynamic PTM such as other better-characterized post translational 
modifications.  
However, the majority of these studies, with the exception of the one from Geoghegan 
and co-workers, do not rely on strategies for the high-confidence validation of in vivo 
methylated sites, such as the hmSILAC and i-Methyl SILAC. This is a sever restrain, since 
it has recently demonstrated very clearly that the identification of methylated peptides with 
label-free approaches implicates quite high FDR in methyl-assignment. Indeed, 
minimizing the FDR is essential when detecting methyl-sites in global studies, because 
incorrect assignments can severely mislead follow-up functional analyses [44].  
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3. AIM OF THE PROJECT 
 
Although microRNA biogenesis is a tightly controlled process, its deregulation, generally 
caused by alteration in the proteins of the pathway, has been observed in different 
pathological conditions, including cancer, and leads to aberrant miRNA expression [4, 
130]. Hence, dissecting the molecular mechanisms underlying miRNA biogenesis is 
crucial to understand how this process is altered in pathological conditions, with the final 
aim of developing possible therapeutic strategies to revert aberrant miRNA levels. 
During miRNA biogenesis, the Large Drosha Complex (LDC) catalyzes the cleavage of 
the primary-miRNAs to precursor-miRNAs, a rate-limiting step for the production of mature 
miRNA molecules, occurring in the nucleus. The enzymatic activity of the complex is finely 
tuned through multiple regulatory mechanisms, including post translational modifications 
(PTM) of its subunits. Our finding that protein methylation frequently occurs on most of the 
proteins of the complex [1] suggested for the first time that this PTM could have a role in 
regulating the complex, and hence in miRNA maturation.  
The aim of my project is to investigate the role of protein methylation in the regulation of 
the LDC structure and function. To this aim, I have first characterized the methylated sites 
occurring on the different subunits of the complex and created a library of high-confident 
LDC methylations. I then focused on PRMT1, the major type I Protein Arginine 
Methyltransferase in mammalian cells, assessing the impact of its modulation (both 
depletion and induction) on the methylation state of LDC. The discovery of novel PRMT1 
targets within the complex, achieved through a systematic and functional MS-based 
analysis, will help shedding light on the mechanisms through which protein R-methylation 
can regulate LDC structure and function, and ultimately impact on miRNA production. 
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4. MATERIALS AND METHODS 
 
4.1 Cell culture 
HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% Fetal Bovine Serum (FBS, Invitrogen 10270-106), 1% glutamine, 100 U/ml 
penicillin, 100 mg/ml streptomycin and cultured at 37°C in a 5% CO2 humidified 
atmosphere.  
 
4.1.1 Heavy methyl SILAC labeling of cells 
HeLa S3 cells were cultured in „„Light‟‟ and „„Heavy‟‟ SILAC media (PAA, custom) 
supplemented with L-Arginine (Sigma Aldrich, A6969) L-Lysine (Sigma Aldrich, L8662), 
and either L-[13CD3]-Methionine (Met-4, heavy, Sigma Aldrich, 299154) or L-[12CH3]-
Methionine (Met-0, light, Sigma Aldrich M5308), respectively. Concentrations of amino 
acids were 84 mg/L, 146 mg/L and 30 mg/L, for L-Arginine, L-Lysine and L-Methionine, 
respectively. The SILAC medium was then supplemented with 10% dialyzed FBS (26400-
044 Gibco, Life Technology), 1% glutamine, 100 U/ml Penicillin and 100 mg/ml 
Streptomycin and 10 mM HEPES pH 7.5.   
Cells were grown in hmSILAC media for at least 9 replication cycles to ensure full 
incorporation, with a careful monitoring of growth rate, viability and overall morphology, 
which ensured that normal physiology, was preserved. 
 
4.1.2 SILAC labeling of cells 
HeLa cells were grown in „„Light‟‟ and „„Heavy‟‟ SILAC DMEM (Thermo Fisher Scientific 
88420), supplemented with either normal L-Arginine and L-Lysine, or their heavy isotope-
counterparts L-Arginine (Arg10, Sigma 608033) and L-Lysine (Lys 8, Sigma 608041). 
Arginine and Lysine were added at a concentration of 84 mg/L and 146 mg/L, 
respectively. The SILAC medium was then supplemented with 10% dialyzed FBS (26400-
044 Gibco, Life Technology), 1% glutamine, 100 U/ml Penicillin and 100 mg/ml 
Streptomycin and 10 mM HEPES pH 7.5.  
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Cells were grown in SILAC media for at least 9 replication cycles to ensure full 
incorporation, with a careful monitoring of growth rate, viability and overall morphology. 
 
4.2 Cell lysis and sub-cellular fractionation 
For the preparation of whole cell extracts cells were collected, washed twice with cold 
PBS 1X and resuspended in 3 volumes of hot SDS Lysis buffer (0.1M Tris HCl pH 7.5, 
SDS 4%). Cells were sonicated 10 sec and then centrifuged 15 min at 13000 rpm. SDS 
total lysates were quantified using BCA (Pierce BCA Protein Assay kit, 23225). 
For sub-cellular fractionation cells were harvested, washed twice with cold PBS 1X and 
re-suspended in 2 volumes of Lysis buffer A (10mM Hepes KOH pH 7.9, 1.5mM MgCl2, 
10mM KCl, 0.2% NP40, 1X Roche Protease Inhibitors, 1U/l NEB RNAse Inhibitors). After 
20 strokes with a dounce homogenizer, cells were centrifuged 15 min at 3750 rpm. 
Supernatant (cytoplasmic extract) was collected and pellet (corresponding to crude nuclei) 
was washed twice with PBS 1X and re-suspended into 2 volumes of buffer C (420mM 
NaCl, 0.1% NP40, 0.5mM DTT, 20mM Hepes KOH pH 7.9, 2mM MgCl2, 0.2mM EDTA 
and 20% glycerol, 1X Roche Protease Inhibitors, 1U/l NEB RNAse Inhibitors). The 
suspension was rotated 1h at 4°C and then ultracentrifuged at 33000 rpm for 1h.  
For subsequent small RNA analysis, the chromatin pellet was washed with 10 volumes of 
buffer C, resuspended in Ripa buffer (10mM Tris HCl pH 8, 150mM NaCl, 0.1% SDS, 1% 
Triton, 1mM EDTA, 0.1% Na Deoxycholate) and centrifuged 5 min at 13000 rpm at 4°C.  
Protein extract were quantified with Bradford assay. 
 
4.3 Protein co-immunoprecipitation (co-IP) 
Nuclear protein extract was quantified with Bradford assay and 1-2 mg of extract was 
diluted with Ripa buffer lacking NaCl to decrease salt concentration to 150 mM NaCl. The 
extract was pre-cleared 3 times with 50 l of Dynabeads-G beads, previously blocked with 
0.5% BSA. After overnight IP, already blocked and washed beads were added to the 
extract and then incubated for 2.5 hours on a rotating wheel. Beads were then washed 4 
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times with Ripa buffer and then incubated with LSD Sample buffer supplemented with 100 
mM DTT in order to elute the immunoprecipitated proteins. Proteins were resolved on 4-
12% Bis-Tris acrylamide SDS-PAGE pre-cast gels (Novex Tris-Glycine Gels, Life 
technologies) and visualized on the gel using Colloidal Coomassie staining (Instant Blue, 
Expedeon), while one tenth was loaded on hand-made linear gel for western blot 
validation. The following antibodies were used for IP according to the manufacturer‟s– 
instruction: DGCR8 (Abcam ab90579, 4 g/mg lysate), FUS (Bethyl A300-293A, 2 g /ml 
lysate), DDX5 (Abcam ab126730, 1/50), Drosha (Santa Cruz sc-33778, 4 g /ml lysate). 
 
4.4 In-gel digestion of immunoprecipitated proteins 
Processing of gel-separated proteins prior MS analysis was carried out as previously 
described, with minor modifications [145]. Briefly, slices were cut from gels and de-stained 
in 50% v/v acetonitrile (ACN)/50 mM NH4HCO3. Reduction was carried out with 10 mM 
DTT, followed by alkylation with 55 mM iodoacetamide. After each step samples were 
dehydrated with 100% ethanol and quickly „„dried‟‟ in a centrifugal evaporator (SpeedVac). 
Subsequently, gel pieces were washed extensively with 50 mM NH4HCO3 and digested 
with 12.5 ng/l trypsin (Promega V5113) overnight at 37°C. Digested peptides were 
extracted with extraction buffer (3% TFA, 30% ACN) and 100% ACN. Prior to MS, 
peptides are desalted and concentrated in a single step through reversed phase 
chromatography on micro-column called C18 Stage Tips [146]. Here, the separation 
depends on the hydrophobic interaction between the solute in the mobile phase and the 
immobilized stationary phase, which consist of hydrophobic C18 resin. The resin is 
composed of eighteen carbon atoms, and therefore is suitable for the binding and 
separation of small poly-peptides. Stage Tips are prepared by placing three disks of 
Empore™ C18 47 mm Extraction Disks (Model 2215, 3M) in an ordinary P200 pipette tip. 
Stage Tips were activated with 100% methanol (CH3OH) and equilibrated twice with buffer 
A (0.1% TFA, 0.5% acetic acid). Tryptic digested samples were diluted in buffer A and 
loaded on the Stage Tips.  Samples were then eluted from the tips with high organic 
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solvent (80% ACN, 0.5% acetic acid), lyophilized, re-suspended in 1% TFA and subjected 
to LC-MS/MS analysis.  
 
4.5 Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS) 
Peptide mixtures were analyzed by online nano-flow liquid chromatography tandem mass 
spectrometry using an EASY-nLC™ 1000 (Thermo Fisher Scientic, Odense, Denmark) 
connected to a quadrupole/Orbitrap mass spectrometer (Q Exactive, Thermo Fisher 
Scientific) through a nanoelectrospray ion source. The nano-LC system was operated in 
one column set up with a 25 cm analytical column (75 μm inner diameter, 350 μm outer 
diameter) packed with C18 reversed-phase resin (ReproSil, Pur C18AQ 1.9 μm, Dr. 
Maisch, Germany) configuration. Solvent A was 0.1% formic acid (FA) and 5% ACN in 
ddH2O and solvent B was 80% ACN with 0.1% FA. Peptides were injected at a flow rate 
of 500 nl/min and separated with a gradient of 5–40% solvent B over 90 min, followed by 
a gradient of 40–60% for 10 min and 60–80% over 5 min at a flow rate of 250 nl/min. The 
Q Exactive was operated in the data-dependent mode (DDA). HCD-fragmentation method 
when acquiring MS/MS spectra consisted of an Orbitrap full MS scan followed by up to 10 
MS/MS experiments (Top10) on the most abundant ions detected in the full MS scan. 
Mass spectrometer conditions for all experiments were as follows: full MS (AGC 3e6; 
resolution 70,000; m/z range 300-1650; maximum ion time 20 ms); MS/MS (AGC 17,500; 
maximum ion time 50 ms; isolation width 1.8 Da with a dynamic exclusion time of 20s). 
Singly charged ions and ions for which no charge state could be determined were 
excluded from the selection. Normalized collision energy was set to 28%; spray voltage 
was 2.2 kV; no sheath and auxiliary gas flow; heated capillary temperature was 275°C; S-
lens RF level of 60%. 
 
4.6 Assigning hmSILAC/SILAC peptide sequences using MaxQuant and data 
analysis 
Acquired Raw data were analyzed using the integrated MaxQuant software v1.3.0.5 or 
v.1.5.2.8, using the Andromeda search engine [147] [100]. The January 2014 version of 
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the Uniprot sequence was used for peptide identification. Enzyme specificity was set to 
Trypsin/P, meaning that trypsin cleavage occurs also in the presence of proline after 
Lysine or Arginine residues. In MaxQuant, the estimated false discovery rate (FDR) of all 
peptide identifications was set to a maximum of 1%. The main search was performed with 
a mass tolerance of 6 ppm. A maximum of 3 missed cleavages were permitted, and the 
minimum peptide length was fixed at 6 amino acids. Carbamidomethylation of cysteine 
was set as a fixed modification.  
 
4.6.1 hmSILAC peptide assignment and data analysis 
To assign hmSILAC peptide sequences, we defined new modifications in MaxQuant 
(v1.3.0.5) with the mass increment and residue specificities corresponding to the heavy 
versions of mono-methylated K/R, di-methylated K/R, and tri-methylated K. Additionally, 
we defined new modifications for heavy methionine and oxidized heavy methionine. To 
reduce the complexity of the search, and given the computational resources available, 
each experimental set of raw data was analyzed three times with three distinct sets of 
variable modifications, namely: (1) N-terminal Acetylation, Met4, Met4ox, oxidation, mono-
methyl-K/R, mono-methyl4-K/R; (2) N-terminal Acetylation, Met4, Met4ox, oxidation, di-
methyl-K/R, di-methyl4-K/R; (3) N-terminal Acetylation, Met4, Met4ox, oxidation, tri-
methyl-K, tri-methyl4-K. Identification of high-confidence methylated sites was carried out 
as previously described [1]. Briefly, we developed a Perl analytical pipeline that filters and 
integrates the output tables from MQ, to identify hmSILAC doublets (pairs) of methylated 
peptides (Fig. 9).  The script pairs peptides containing the same MQ-assigned 
modification in both heavy and light form, applying the following criteria: (1) first the 
peptide pairs that were not present in the same RAW file or that were not assigned the 
same charge state were excluded; (2) the peptide sequences annotated as containing 
heavy and light forms of modifications simultaneously were excluded; (3) heavy and light 
peptides were required to have an Andromeda score > 62; (4) all remaining methyl-
peptides were required to have the modification localized with a probability score > 0.75.  
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Fig. 9 Schematic description of hmSILAC data processing through an analysis 
pipeline developed in-house. 
RAW data generated upon LC-MS/MS analysis, were processed using the MaxQuant 
software v1.3.0.5. Each experimental set of RAW data was analyzed three times in 
parallel, with distinct sets of variable modifications: (1) N-terminal Acetylation, Met4, 
Met4ox, oxidation, mono-methyl-K/R, mono-methyl4-K/R; (2) N-terminal Acetylation, 
Met4, Met4ox, oxidation, di-methyl-K/R, di-methyl4-K/R; (3) N-terminal Acetylation, Met4, 
Met4ox, oxidation, tri-methyl-K, tri-methyl4-K. The MaxQuant outputs were processed 
using an in-house Perl script (light blue boxes) that filters MS/MS spectra to identify 
hmSILAC pairs, following the criteria displayed in the picture. The Perl pipeline output 
consists in a .txt table listing high-confidence identified in vivo methylated peptides.  
 
4.6.2 SILAC peptide assignment and data analysis 
SILAC peptide and protein quantification was performed automatically with MaxQuant 
(v.1.5.2.8) using default settings for parameters. N-terminal acetylation of protein, 
methionine oxidation mono-methyl-K/R, di-methyl-K/R and tri-methyl-K were set as 
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variable modifications in MaxQuant. Outputs from MQ were manually filtered as fallow: 
proteins were accepted if identified with at least two peptides of which at least one unique; 
protein quantified were considered for further analysis only if they have ratio count (RC) 
equal or greater than 1.  
A data analysis pipeline, written in Perl, was developed in-house to process MaxQuant 
output. In this pipeline, the evidence.txt file was first filtered: potential contaminants and 
reverse sequences were removed, and all accepted methyl-peptides were required to 
have all described methylations localised with a probability score >0.75. No Andromeda 
score cut-off was imposed. For quantitative analysis, methyl-peptides ratios were 
normalised on protein-level H/L information within each IP experiment and the median 
ratio of redundant methyl-peptides was calculated. To define significantly regulated 
methyl-peptides upon PRMT1 KD, for each IP experiment, the mixtools R-package 
(www.r-project.org) was used to define three Gaussian distribution related to three methyl-
peptide populations: depleted, background and enriched. The mean and standard 
deviation (SD) of the background population were then used to define statistically 
significant- regulated peptides in each IP experiment.  
Localization analyses of methylated peptides were performed using the Pfam database 
(http://pfam.xfam.org/), the Eukaryotic Linear Motif (ELM) resource (http://elm.eu.org/) or 
RCSB PDB (http://www.rcsb.org/pdb/home/home.do). 
 
4.7 Cell transduction with lentiviral vectors  
HeLa cells were transduced using second-generation lentiviral vectors, whose stocks 
were produced by the transient transfection of 293T cells with the packaging plasmid 
pCMV-DR8.74, the envelope plasmid pMD2G-VSVG and the respective transfer gene-
carrying vector.  
To knock down (KD) PRMTs, cells were infected with two different sh-RNAs targeting 
PRMT1, PRMT4, PRMT5, PRMT6 and PRMT7 or with plkO-Empty vector as a control 
(kindly provided by E. Guccione, IMCB Singapore). Sh-Scr and sh-Luciferase vectors 
were also tested as controls. 
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To overexpress PRMT1, the cDNA of the v2 isoform was amplified starting from cDNA of 
HeLa using the following primers:  
FW –GGGGATCCCCCGGGCTGCAGATGGCGGCAGCCGAGGCCGCGAACTGCA-  
REV –GAGGTTGATTGTCGACTCAGCGCATCCGGTAGTCGGTGG- 
PRMT1 cDNA was cloned into pCCLsin.CPPT.PGK.GFP.WPRE lentiviral vector after 
plasmid linearization with PstI and SalI using the in-fusion HD EcoDry cloning plus 
according to the manufacturer‟s instructions (Clontech Laboratories, Inc., CA). The GFP 
cassette was removed from the vector after digestion with XhoI. 
For virus preparation 293T packaging cells were plated (DMEM, 10% heat-inactivated 
FBS, 2mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin) and co-transfected 
with 4 μg of pMD2G-VSVG, 6 μg of pCMV-DR8.74 and 10 μg of either the empty vector or 
the vector carrying the shRNA sequences. After 15 min 20 M final of cloroquine was 
added to inhibit lysosomal degradation of exogenous DNA. After few hours the medium of 
293T packaging cells was replaced with fresh medium. Supernatants from transfected 
293T were collected at 48 hours post-transfection and used for HeLa infections. HeLa 
were infected at 50% of confluence and after 6-8 hours the virus-containing medium was 
gently removed and replaced by fresh medium. Puromycin selection (1 μg/ml) started 24 
hours after the infection.  
 
4.8 Western Blot analysis 
Protein extracts from IP or cellular extracts were resolved by SDS-PAGE electrophoresis 
and blotted on PVDF membrane (Immobilon PVDF, Merck). Membrane blocking (10% 
BSA, TBS 0.1% Tween-20 for 1 hour) was followed by incubation with the appropriate 
primary antibodies and HRP-conjugated secondary antibodies (Cell Signaling 
Technology). Proteins were revealed by ECL system (Clarity ECL Western Substrate, 
Biorad) and chemo luminescence was measured with a ChemiDoc instrument (Biorad). 
The following antibodies were used, according to the manufacturer‟s instructions, at the 
indicated dilutions:  DDX5 (1:100), DGCR8 (1:10000), FUS (1:1000), DROSHA (1:1000), 
VCL (Millipore 06-866, dilution 1:10000), PRMT1 (Abcam ab73246, 1:1000), PRMT4 
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(Bethyl A300-421A, 1:5000), PRMT5 (Abcam ab109451, 1:10000), PRMT6 (Abcam 
ab47244, 1:1000) , PRMT7 (sc-98882, 1:200), ASYM24 (Millipore, 1:1000), SYM10 
(Millipore, 1:1000), MeR4-100 (Cell Signaling Technology 8015, 1:1000), LAMIN A/C (sc-
6215, 1:1000), Lamin B (Abcam ab16048, 1:1000), GAPDH (Abcam ab9484, 1:1000), H3 
(Abcam ab1791, 1:5000), H4 (Abcam ab7311, 1:5000), H4R3me2a (Active Motif 39705, 
1:1000), ILF3 (Bethyl A303-615A, 1:2000), ILF2 (sc-271718, 1:1000), DDX17 (sc-130650, 
1:1000), DDX3 (LS-C64573, 1:5000). 
 
4.9 Total and small- RNA extraction 
Total and small- RNA were prepared using mirVANATM miRNA Isolation kit (Ambion), 
according to the manufacturer‟s specification.  
For the analysis of small-RNA in distinct cellular compartments, RNA was isolated from 
the chromatin fraction, the nucleosol and the cytosol by adding 1ml of Trizol (Trizol LS 
Reagent, Ambion) and 200 l of chloroform to each fraction. The solution was mixed, 
incubated 5 min at RT and then centrifuged at 13000 rpm for 15 min at 4°C. The aqueous 
phase containing the RNA was collected and loaded on miRVANA column for RNA 
isolation.  
DNAse (Zymo Research) treatment of RNA was performed before reverse transcription. 
 
4.10 cDNA synthesis and real-time PCR 
The cDNA was produced using the reverse-transcriptase miScript II RT Kit (Qiagen), 
starting from 1 g of total RNA, according to the manufacturer‟s specifications for mRNA, 
pri-miRNA, pre-miRNA and miRNA profiling. One tenth of the reaction was used for Real-
time PCR reactions in a 7,500HT Fast Real-Time PCR System. miScript SYBR Green 
PCR Kit (Qiagen) was used for miRNA and pre-miRNA analysis, following manufacturer‟s 
instruction, while mRNA and pri-miRNA were analyzed with FAST Sybr Green Master Mix 
(Life Technologies).  
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4.11 Primers used for quantitative PCR 
For primary miRNA analysis we designed standard quantitative PCR (qPCR) primers that 
match a region just before the stem loops of each miRNA cluster under investigation (Fig. 
10A). Since the mature miRNAs of a cluster originates from the same primary transcript, 
miR-15a and miR-16-1 share the same pri-miRNA, likewise all the miRNAs of miR-17/92. 
MicroRNAs miR-15a, miR-16-1, miR-17, miR-18, miR-19a, miR-19b, miR-20, miR-92, 
miR-150 were amplified using forward primers from miScript primer assays (Qiagen) and 
reverse universal primers from miScript SYBR Green PCR Kit (Qiagen). Briefly, mature 
miRNAs are not polyadenylated, thus, when reverse transcription reactions are performed 
using miScript RT kit from Qiagen, mature miRNAs are polyadenylated by poly(A) 
polymerase and reverse transcribed in cDNA using oligo-dT primers. The oligo-dT primers 
have a 3‟ degenerate anchor and a universal tag sequence on the 5‟ end allowing 
amplification of mature miRNA in the real-time PCR step. In fact, the combination of the 
forward primer (miScript Primer Assay) with the miScript SYBR Green PCR Kit allows 
miRNA amplification.   
Since precursor miRNAs are not polyadenylated, we adapted the miScript Qiagen 
strategy for miRNA analysis also to precursor amplification. We designed forward primers 
specific for the stem-loop sequences of each pre-miRNAs of interest and exploited the 
reverse universal primer from the miScript SYBR Green PCR Kit (Fig. 10B, upper panel). 
Upon qPCR amplification, the strategy we used resulted specific for mature and precursor 
miRNAs detection (Fig. 10B, lower panel).  
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Fig. 10 qPCR primer designed for pri-, pre- and mature miRNAs analysis 
A) Schematic representation of the strategy used to design specific qPCR primers for pri-
miRNAs. B) Upper panel: schematic representation of the strategy used to design specific 
qPCR primers for pre-miRNAs amplification (in green) and comparison with Qiagen 
mature miRNAs primers (in red). Grey boxes represent the reverse universal primers. 
Lower panel: visualization of the qPCR products obtained using primers specific for 
mature and precursor miR-15a and miR-16-1 (representative of all miRNAs tested); 
mature miRNAs are shorter than the corresponding precursors.  
 
Primer sequences are the following: 
DGCR8: Fwd AAAACTTGCGAAGAATAAAGCTG,  
  Rev TCTGTTTAACAAAGTCAGGGATGA 
pri-miR-15a/16-1: Fwd GCCCTGTTAAGTTGGCATAGC,  
     Rev ACTGAAGTCCATTCTGTGCCC 
pri-miR-17/92: Fwd TGCCACGTGGATGTGAAGAT,  
 Rev GGCCTCTCCCAAATGGATTGA 
pre-miR-15: Fwd CCTTGGAGTAAAGTAGCAGCACA 
pre-miR-16: Fwd CAGTGCCTTAGCAGCACGTA  
pre-miR-17: Fwd AAAGTGCTTACAGTGCAGGTAGT 
pre-miR-18: Fwd GGTGCATCTAGTGCAGATAGTGA 
pre-miR-19a: Fwd GTCCTCTGTTAGTTTTGCATAGTTG  
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pre-miR-19b: Fwd GTTAGTTTTGCAGGTTTGCATCC  
pre-miR-20: Fwd GTAGCACTAAAGTGCTTATAGTGCAGG  
pre-miR-92: Fwd CTACACAGGTTGGGATCGGT  
 
4.12 Taqman Array Human microRNAs 
For the global analysis of miRNAs we used TaqMan Array Human microRNA A+B Cards 
(Applied Biosystems). In this case small RNA was prepared using mirVANATM miRNA 
Isolation kit (Ambion), and cDNA was prepared using MegaplexTM RT reaction kit (Applied 
Biosystems).  
Data were normalized on the geometric mean of a panel of housekeeping genes 
(MammU6, U6snRNA). MicroRNAs were considered significantly up/down-regulated when 
greater/lower than 1.5 fold changes. 
 
4.13 Small-RNA sequencing: preparation of libraries, sequencing and data analysis 
1 g of total RNA was used as input for libraries preparation with the TruSeq Small RNA 
Library Prep Kit (Illumina), following manufacturer‟s instructions.  
Briefly, RNA 3‟ and RNA 5‟ adapters were sequentially ligated to the RNA. Reverse 
transcription followed by PCR was used to create cDNA constructs based on the small 
RNA ligated with the adapters. The resulting cDNA constructs were gel-purified, eluted 
and concentrated by ethanol precipitation. The DNA fragment library was quantified with 
Bioanalyzer (Agilent Technologies) and sequencing was performed on an Illumina 
HiSeq2000 at 50bp single-read mode and 20 million read depth. Data analysis was 
performed with the IsomiRage workflow, as previously described [148]. Data normalization 
was performed after reads mapping, assignment and filtering. Normalization of the data 
was performed with a reads-per-million (RPM) normalization, using small nucleolar RNAs 
(snoRNA) or canonical miRNAs reads in each sample as normalizer.  
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5. RESULTS 
 
5.1 Characterization of the Large Drosha Complex methylation pattern 
In order to carry out a comprehensive analysis of the methylation pattern of the LDC, we 
set up a strategy combining the hmSILAC approach with affinity enrichment of the 
complex, followed by mass spectrometry analysis. As outlined in the Introduction 
(paragraph 2.6.3), the hmSILAC approach allows improving the confidence in methyl-site 
identification, overcoming several limitation of MS-based analysis of this type of 
modification in label-free mode, thanks to the specific isotope labeling of in vivo 
methylation. Moreover, the co-immunoprecipitation (co-IP) of the LDC facilitates the 
enrichment of all components of the complex, independently from their abundance in the 
cell. This aspect is crucial to increase the MS-coverage of all 23 subunits of the LDC and 
boost the comprehensive identification of methylations also on sub-stoichiometric 
proteins.  
The strategy followed is outlined in Fig. 11. Briefly, HeLa S3 cells were metabolically 
labeled with the two isotopic variants (light, L and heavy, H) of methionine, up to full 
incorporation. Labeled cells were harvested, mixed in equal amount (1:1) and cell extracts 
fractionated into nuclear and cytosolic extracts. Nuclei were used as input for the immuno-
affinity enrichment of the complex by co-IP and the immunoprecipitated material was 
separated on SDS-page and subjected to in-gel digestion with trypsin prior to LC-MS/MS. 
In parallel, the IP of the baits and the co-IP of some other subunits of the LDC, were 
validated through western blot (WB). Upon MS analysis, the high-confidence identification 
of in vivo mono-, di- and tri-methylated peptides was achieved taking advantage of the 
hmSILAC labeling: upon mixing H/L cells in 1:1 ratio, the in vivo methylated peptides 
result in the MS spectra as peptide-pairs separated by a specific mass difference 
corresponding to the number of methyl-groups present. 
 44 
 
 
 
Fig. 11 Description of the hmSILAC/co-IP approach to characterize the LDC 
methylome 
HeLa S3 were metabolically labeled with the light (Met-0, black dish) and heavy (Met-4, 
green dish). Cells were harvested, mixed 1:1 and subjected to fractionation into cytosolic 
and nuclear extracts. The nucleosol was used as input for the immuno-affinity enrichment 
of the complex, by co-IP, using different subunits of the complex as baits. The precipitated 
proteins were in-gel digested with trypsin, and analyzed with LC-MS/MS. Upon MS 
analysis, the type of methylated residue can be identified on the basis of the mass 
separation of the peptide pair (4 Da = mono-methylation, 8 Da = di-methylation, 12 Da = 
tri-methylation). In parallel, each co-IP was validated through WB analysis.  
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5.1.1 Heavy methyl SILAC labeling of HeLa S3 
HeLa S3 cells were cultured in SILAC DMEM supplemented with light Arginine and Lysine 
and either heavy (Met-4) or light (Met-0) methionine, in parallel. Moreover, the SILAC 
medium contains heat-inactivated and dialyzed FBS, to ensure that the isotope-coded 
light (Arg-0, Lys-0, and Met-0) and heavy (Met-4) amino acids represent the only source 
of amino acids used for new protein synthesis. Growth curves of HeLa S3 cultured in light 
and heavy media are comparable (Fig. 12A), indicating that cell viability is not influenced 
by the different isotope-coded amino acid composition of the media.  
Cells were cultured in heavy hmSILAC medium for nine replications and the incorporation 
rate of heavy methionine was then assessed; upon cell lysis, the total extract was 
separated on SDS-PAGE and MS-analyzed upon in-gel trypsin digestion. The percentage 
of heavy methionine-containing peptides was evaluated by quantitative MS: out of 1031 
peptides containing methionine identified, 795 (77%) were present only in the heavy form 
and only 8 in the light form, whereas 214 peptides were identified in both heavy-Met and 
light-Met forms. The distribution of heavy-Met/light-Met ratios associated to these peptides 
allowed to estimate an incorporation rate of 95% (Fig. 12B). The almost complete 
incorporation of heavy methionine in HeLa S3 cell was therefore suitable for further 
experiments.  
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Fig. 12 Heavy methyl SILAC labeling of HeLa S3 cells  
A) Comparison of the growth curves of heavy-labeled (red) and light-labeled (blue) cells. 
B) Heavy methionine (Met-4) incorporation rate in HeLa S3. The Table summarizes the 
number and corresponding percentages of peptides identified in each form.  
 
5.1.2 Nuclear and cytosolic sub-cellular fractionation of HeLa S3  
The LDC is a nuclear complex and, even if many of its components shuttle between 
nucleus and cytosol, the majority of them are usually located in this cell compartment. For 
this reason, we decided to optimize the affinity enrichment of the complex using as input 
nuclear extracts.  
 We optimized a cell fractionation protocol (described in details in Materials and Method, 
paragraph 4.2) that allows an efficient separation of cytosol and nucleus, as confirmed by 
the correct localization of cytoplasmic (Vinculin) and nuclear (Lamin A/C) markers profiled 
by Western blot (WB) (Fig. 13A). Moreover, this protocol allows further separating the 
nucleosol from the chromatin fraction, which was excluded from the analysis since we 
want to favor the identification of non-histone methylation.  As a matter of fact, histones 
A 
B 
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are highly methylated and very abundant in the nucleus and shotgun proteomic 
approaches, including MS-based analysis of PTMs, have a bias towards more abundant 
proteins. Hence, the choice of using nucleosolic extracts as input for the enrichment of the 
complex, excluding both cytosol and chromatin, was strategic to support in-depth 
annotation of the LDC methyl-proteome. 
 
5.1.3 Co-immunoprecipitation of the Large Drosha Complex 
The LDC is a large multi-protein complex with several subunits (like DDX5, DDX17 and 
DHX9) that are also engaged in other complexes, such as the spliceosome. Hence, to be 
able to enrich efficiently the complex in its completeness, we set up co-IP protocols using 
four different subunits as bait: DGCR8 and Drosha -which constitute the core components 
of the LDC- and the two associated proteins DDX5 and FUS. Using unlabeled nuclear 
extract, we first carried out an extensive optimization of the co-IP protocols, testing each 
antibody against the four different baits, in order to achieve the highest coverage of the 
LDC (both in terms of number of subunits identified and of their protein coverage by MS) 
and to reduce the cross-contamination with background proteins. The co-enrichment of 
other subunits of the complex with the baits was validated by WB (Fig. 13B) and the 
precipitated proteins were loaded on SDS-page and Coomassie-stained. Each IP and 
input was cut in 9 gel slices and in-gel digested (see Materials and Methods, paragraph 
4.4) with trypsin, prior to MS analysis (Fig. 13C).  
We identified reproducibly all subunits of the complex in all experiments performed. 
However, DGCR8 was identified only when either the protein itself or Drosha were used 
as baits, which indicates that DGCR8 is a low abundant protein and becomes detectable 
only when enriched through direct protein-protein interaction with its partner in the core 
complex. The 23 subunits of the complex were identified in the different experiments with 
overall average sequence coverage of 40% (Fig. 13D). To validate the efficiency of each 
IP in enriching the complex, the normalized Label Free Quantitation (LFQ) intensity values 
of the LDC components were compared to the intensities of the background proteins: the 
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shift in the median LFQ values indicated the efficient enrichment of the complex, 
compared to background (Fig. 13E).  
 
 
 
Fig. 13 Optimization of the co-IP protocols for the enrichment of the Large Drosha 
Complex 
A) WB validation of HeLa S3 sub-cellular fractionation. Vinculin (VCL) and Lamin A/C 
were used as marker for cytoplasm and nucleus, respectively. Increasing amounts of 
extracts (10 and 20 g) were used for the analysis. B) WB validation of the co-IP of some 
subunits of the complex together with the four baits used (labeled in red). 
Immunoprecipitation with Immunoglobulin G (IgG) was used as negative control. FT = 
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Flow-through. C) Coomassie-stained gels of the optimized co-IPs are illustrated. Dashed 
lines indicate the slices in which each lane was cut for protein in-gel digestion and peptide 
extraction, prior to LC-MS/MS. D) List of the subunits identified by MS using DGCR8, 
Drosha, DDX5 and FUS as baits in the co-IP. The mean sequence coverage of each 
protein from the four different IPs is indicated. E) Efficiency of each IP in enriching the 
complex was assessed comparing the normalized LFQ intensity values of the LDC 
subunits in the IPs, to those of the background: the shift in the median LFQ intensities 
represents the enrichment of the complex compared to background proteins.  
 
5.1.4 Features of the Large Drosha Complex methyl-proteome 
Upon the optimization of the affinity-enrichment protocol with unlabeled extracts, we 
performed the IP experiments using hmSILAC-labeled nuclear extract as input, to 
characterize the methylation pattern of the LDC. Upon five independent co-IPs followed by 
MS analysis and data processing (as described in details in Materials and Methods, 
paragraph 4.6 and 4.6.1) we identified 94 individual methylations on 68 distinct sites, on 
14 out of 23 proteins of the complex. Combining these results with those obtained in our 
previous global analysis of methylation based on hmSILAC [1], we extended the 
annotation of high-confidence in vivo methylated sites for the LDC to 123 modifications on 
90 sites, occurring on 17 of the 23 components of the complex (Fig. 14A, appendix 1), 
confirming our previous observation that the Large Drosha Complex is highly methylated. 
 The majority of modifications occurs on Arginine (R) residues (86%), which are equally 
mono- or di-methylated, with a significant proportion of residues identified in both forms, 
while the few Lysines (K) identified are mostly mono-methylated (Fig. 14B). Interestingly, 
the analysis of the methyl-sites localization within protein sequences revealed that the 
majority of all identified sites (89%), as well as the one of R-sites (90%), were localized 
within Low Complexity (LC)/ disordered regions (Fig. 14C). LC regions are sequences 
with very little variation in their amino acid composition, to which a role in mediating 
protein sub-cellular localization, protein-protein and protein-RNA interactions has been 
ascribed, especially for RNA-binding proteins [149-152].  
Our combined strategy allowed not only to confirm many of the sites annotated in our 
previously published dataset [1], but also to identify novel modification sites also on 
proteins not described as methylated before (Fig. 14D). Finally, we could also generate a 
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comprehensive library of high-confidence methylations on the LDC, to be used as a 
reference for all further functional experiments on methyl-dynamics. 
Overall, these results confirmed that methylation, especially on R, massively modifies the 
LDC corroborating the hypothesis that this modification may play a crucial role in the 
regulation of its composition and/or function. 
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Fig. 14 Features of the in vivo methyl-proteome of the Large Drosha Complex 
A) Summary of the LDC methyl-proteome. B) Distribution of R and K methylations 
identified on the complex (left panel) and R and K methyl-proteome composition (right 
panel). C) Pfam localization analysis of all the sites identified and of the R sites (LC= Low 
Complexity regions). D) Comparison between previously identified methyl-sites on the 
complex [1] and the novel identifications achieved through the combination of hmSILAC 
and co-IP/MS.  
 
5.2 Set up of PRMT1 depletion and overexpression to modulate the Large Drosha 
Complex methylation state 
Given the recognized role of protein methylation in regulating the function of other protein 
complexes, such as the spliceosome [42, 153] we explored the possibility that it could also 
regulate the Large Drosha Complex.  
Arginines, which resulted as the most frequently methylated residue on the complex, can 
be modified by a set of arginine methyltransferases (PRMTs) in mammalian cells. Thus, 
we decided to focus on PRMT1, the most abundant and active PRMT [59], and to 
modulate its expression levels both through knock down (KD) and overexpression, with 
the aim of studying if and how methylation on the LDC change and to understand whether 
possible methylation changes may affect the complex function, thus impacting miRNA 
biogenesis.  
The strategy we followed to deplete and overexpress PRMT1 is based on HeLa 
transduction with lentiviral particles carrying either different short hairpin (sh) RNAs 
specific for the enzyme or PRMT1 cDNA respectively, as schematized in Fig. 15. In both 
cases we used Empty vectors as a control. HeLa were harvested upon puromycin 
selection of positively infected cells and subjected to either protein extraction for 
expression and methylation analysis or to miRNA isolation to study the LDC processing 
activity. 
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Fig. 15 Scheme of the strategy used to deplete and overexpress PRMT1 in HeLa 
cells 
Wild-type HeLa cells were transduced with lentiviral particles carrying Empty vector 
(green), different short hairpin RNAs (sh) (light blue) or PRMT1 cDNA (red). Upon 
puromycin selection of infected cells (dashed grey line) cells were harvested and 
subjected to different type of analyses.  
 
5.2.1 Set up of PRMT1 knock down  
For PRMT1 depletion, we initially tested three different sh-RNAs, called sh-B6, sh-B10 
and sh-B8 respectively. Even if they all resulted efficient in achieving the depletion of the 
enzyme, we noticed that PRMT4 and PRMT6 expression was slightly decreased when 
using sh-B8 (Fig. 16A). Hence, we discarded the sh-B8 construct and used sh-B6 and sh-
B10 for the subsequent experiments.  
Although there is evidence that the PRMTs might compensate each other [138], when we 
profiled the expression of other enzymes by WB, none of the sh-RNAs employed led to a 
detectable increase of their protein levels (Fig. 16A). Yet, this does not exclude the 
possibility that the other PRMTs compensate the loss of PRMT1 through mechanisms that 
do not require changes in their expression, such as variation in their activity or substrate 
specificity.  
Loss of PRMT1 expression is reported to be embryonic lethal in mice [154] and for this 
reason we assessed cell growth after its depletion. We performed a growth curve analysis 
starting from 24 hours (h) post cell infection comparing the growth of control and PRMT1 
KD cells. Up to 96h after the infection, the growth of PRMT1-depleted cells is comparable 
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to control (Fig. 16B, left panel). However, starting from 96h post infection, PRMT1 
depletion starts to affect cell viability, ultimately being not compatible with cell growth at 
later time points (Fig. 16B, right panel).   
We thus profiled global methylation changes by WB after infection. Taking advantage of 
anti-pan-methyl antibodies that recognize different forms of R-methylation, we analysed 
asymmetric di-methylation and mono-methylation since they are the types of modifications 
catalyzed by PRMT1. PRMT1 is completely depleted at 48h post infection (PI), using both 
sh-RNAs (Fig. 16C, left panel), while major changes in global methylation can be 
appreciated only at 72 and 96h PI. Indeed mono-methylation is already increasing at 72h 
while di-methylation shows an overall decrease at 96h (Fig. 16C, left panel). Similar 
studies have shown that PRMT1 depletion causes a decrease in asymmetric di-
methylation that corresponds to a strong increase on mono-methylations [138]. Still, it is 
not clear whether this effect is due to compensatory mechanisms or competition by other 
PRMTs or just as a consequence of the lack of di-methylation. Moreover, it has been 
reported that after an initial loss of di-methylation, four days upon PRMT1 depletion its 
levels starts to increase again [138]. We also observed a similar effect when profiling 
asymmetric di-methylation at later time points, up to 6 days PI (Fig. 16C, right panel).  
Based on these data, we chose to perform all following experiments 72 hours after 
PRMT1 KD, on the one hand because of the affected cell viability at later timing and on 
the other hand because of the changes in the global methylation occurring within 4 days 
PI.  
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Fig. 16 PRMT1 KD set up 
A) WB analysis of PRMT1, PRMT4, PRMT5, PRMT6 and PRMT7 expression upon 
PRMT1 KD with three different sh-RNA sequences (sh-B6, sh-B10, sh-B8). Empty is the 
negative control. VCL was used as loading control. B) Growth curves of control and 
PRMT1-depleted cells between 24 and 96 hours post infection (PI) (left panel), and 
between 96 and 192 hours PI (right panel). Dashed grey line at 24h PI indicates 
puromycin selection. C) Time course profiling of PRMT1 depletion, asymmetric di-
methylation (ASYM24) and mono-methylation (mono) between 24 and 96 hours PI (left 
panel). Time course profiling of PRMT1 depletion and of asymmetric di-methylation 
(ASYM24) between 4 and 6 days post infection (right panel). VCL was used as loading 
control. Red asterisks highlight changes in di- or mono-methylation. 
 
5.2.2 PRMT1 overexpression set up 
To achieve the enzyme overexpression in HeLa cells, PRMT1 cDNA was cloned into a 
lentiviral vector following the same strategy used for the knock down. The corresponding 
empty vector was used as a negative control. To evaluate the overexpression efficiency 
and the activity of the ectopic enzyme, we profiled PRMT1 and asymmetric di-methylation 
global changes in a time window between 24h and 96h after the infection. The expression 
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of the protein starts to increase already after 24-48h and correlates with a global increase 
of di-methylations (Fig. 17A, upper panel). 48h PI we observed the increase of 
asymmetric di-methylation of R3 of histone H4 (H4R3me2a), a well-known PRMT1 
histone target [60] (Fig. 17A, lower panel). This result reassured that the gain of 
modification observed was due to the augmented PRMT1 level.  
In HeLa PRMT1 is ubiquitously expressed both in the nucleus and in the cytoplasm. Thus, 
we analysed the localization of the ectopic enzyme, by fractionating control and PRMT1-
overexpressing cells into nuclear and cytosolic extracts. We performed this experiment at 
72h and 96h after the infection because at this time points PRMT1 was highly 
overexpressed. The enzyme expression level is increased in both cell compartments 
compared to the control (Fig. 17B). Accordingly, upon PRMT1 overexpression, we 
observed increased asymmetric arginine di-methylations and decreased mono-
methylations, in particular in the nucleus where the LDC is located and exerts its function 
(Fig. 17B). Moreover, the expression of other PRMTs (PRMT4, 6 and 7) was not affected 
by PRMT1 overexpression (Fig. 17C), suggesting that methylation changes may be due 
to ectopic PRMT1 activity rather than to the activity of other enzymes.  
 
 
 
Fig. 17 PRMT1 overexpression set up 
A) Western Blot profiling of PRMT1 overexpression and of asymmetric di-methylation 
(ASYM24) between 24 and 96 hours PI. VCL was used as loading control (upper panel). 
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Time course profiling of H4R3me2a on the same samples. GAPDH was used as loading 
control (lower panel). B) WB analysis of endogenous and ectopic PRMT1 localization at 
72h and 96h PI. Cells were fractionated into nuclear (Nucl.) and cytoplasmic (Cyto.) 
extracts. Global asymmetric di-methylation and mono-methylation are also profiled. VCL 
was used as cytoplasmic marker. Lamin B was used as nuclear marker. C) WB analysis 
of PRMT1, PRMT4, PRMT6 and PRMT7 expression upon PRMT1 overexpression. VCL 
was used as loading control. 
 
5.3 Identification of PRMT1-specific targets on the Large Drosha Complex 
5.3.1 Analysis of the effect of PRMT1 depletion on the LDC at protein and methyl-
peptides levels 
The strategy we followed to identify PRMT1 targets on the LDC is outlined in figure 18A: 
we combined standard SILAC labeling of control and PRMT1-depleted cells with affinity 
enrichment of the complex by co-IP, followed by high resolution MS analysis and 
MaxQuant quantification of methyl-peptides in the two functional states. Heavy methyl 
SILAC is a useful tool for the high-confidence identification of in vivo methylation sites, but 
it has the limitation that only methionine-containing peptides can be quantified. For this 
reason, having built a reference library of confidently identified methylated sites on the 
LDC, we decided to move to a standard SILAC setup for this type of experiment. 
Moreover, SILAC allows identifying and quantifying peptides through a dedicated software 
package making the quantitation analysis more straightforward and robust [22, 23].  
HeLa cells were labeled by growing them in media supplemented with light (Arg0, Lys0) or 
heavy (Arg10, Lys8) acids. Upon full incorporation, cells were infected with either the 
empty vector or with sh-B6 vector and they were harvested and mixed in equal amount 
(1:1) 72 hours after infection, based on the evidence that protein methylation changes 
appeared to peak at this time point. Cells were fractionated into nuclear and cytosolic 
fraction and the nuclear extract was partly analyzed directly by MS, partly used as input 
for the immuno-affinity enrichment of the complex. We performed three IPs in parallel 
using DGCR8, DDX5 and FUS as baits, in order to identify as many methyl-sites as 
possible. The three IPs were analyzed through geLC-MS/MS and raw data analyzed by 
MaxQuant software, as described in Materials and Methods (paragraph 4.6.2). Within this 
experimental setup, the ratio of the heavy versus the light peak intensity for the methyl-
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peptide of a specific protein reflects potential changes in its methylation state, whereas 
the heavy-to-light ratio of the intensity of the unmodified peptides for the corresponding 
protein are used to normalize over possible changes in protein levels (Fig. 18A). We 
performed both „forward‟ and „reverse‟ experiments by swapping the SILAC channel in 
which PRMT1 was depleted.  
In the “forward” experiment, PRMT1 KD was carried out in the heavy-labeled cells. 
Collected cells were fractionated (Fig. 18B, upper panel) and nuclear extract was used 
as input for the immuno-affinity enrichment of the complex through DGCR8, DDX5 and 
FUS IPs (Fig. 18B, lower panel). The immunoprecipitated material was separated by 
SDS-page; nine slices were excised for gel lane and subjected to trypsin digestion 
followed by MS analysis with a Q Exactive instrument. Upon data analysis, we evaluated 
the efficiency of the IPs in enriching the complex, comparing the iBAQ intensity values of 
the LDC with those of the background proteins. The shift in the median iBAQ intensity 
indicated the successful enrichment of the complex for all the IP experiments (Fig. 18C).  
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Fig. 18 Description of the SILAC/co-IP ‘forward’ experiment for the identification of 
PRMT1-specific targets on the Large Drosha Complex 
A) Workflow of the experimental strategy: a“forward” experimental setup is schematized. 
B) Upper panel: WB analysis of PRMT1 KD and evaluation of cell fractionation; tubulin 
was used as loading control, VCL and Lamin B were used as marker for cytoplasm and 
nucleus, respectively. Lower panel: validation of DDX5, DGCR8 and FUS IPs by WB. IgG 
was used as negative control for IP. FT = Flow Through. C) Coomassie-stained gel of 
DDX5, DGCR8, FUS and IgG IPs. Dashed lines indicate the slices in which each lane was 
cut for protein in-gel digestion and peptide extraction prior to LC-MS/MS. D) Evaluation of 
the efficiency of each IP in enriching the complex. For each IP experiment the iBAQ 
intensities of the proteins of the complex in the light (control) sample were compared to 
those of the background proteins. 
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We then performed a global analysis of the nuclear proteome upon PRMT1 depletion, with 
a specific focus on the LDC subunits, to assess possible changes in their protein 
expression. We examined SILAC ratios for all proteins identified and quantified confidently 
in the nuclear input of both „forward‟ and „reverse‟ experiments. We calculated the mean 
() and standard deviation () of the protein ratio distributions (log2 of H/L and L/H ratios 
in „forward‟ and „reverse‟ experiments, respectively) and defined as significantly up-/down- 
regulated those proteins that were greater or lower than  ± 2(„forward‟: log2 ratios 
greater than 1.01 and lower than -0.966; „reverse‟:  log2 ratios greater than 0.896 and 
lower than -1.174).  Based on the fact that the H/L and L/H protein ratios of the LDC 
subunits lie within these cutoffs, we concluded that their expression was not significantly 
affected by PRMT1 depletion (Fig. 19A, red dots), whereas we could confirm the 
substantial down-regulation of PRMT1 upon sh-B6 (Fig. 19A, blue dot). We validated the 
MS results by WB, confirming that PRMT1 depletion does not affect the expression level 
of some key component of the complex, such as DGCR8 and Drosha (Fig. 19B).  
 
 
 
Fig. 19 Quantitative proteomics to profile changes in nuclear protein levels after 
PRMT1 depletion 
A) The scatterplot shows the log2 SILAC distribution (H/L ratio and L/H ratio for the 
„forward‟ and „reverse‟ experiment, respectively) of the nuclear proteins identified in 
„forward‟ and „reverse‟ experiments, upon PRMT1 KD. PRMT1 is highlighted in blue; the 
components of the LDC are highlighted in red. Dashed lines represent cut off for 
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statistically significant regulated proteins. B) WB analysis of the expression of some key 
components of the complex in control and PRMT1 KD cells (sh-B6). Lamin B and GAPDH 
were used as loading control. Increasing amounts of nuclear extract (10, 20, 30 g) were 
used for the analysis. 
 
Upon MS data analysis of „forward‟ and „reverse‟ experiments by MaxQuant, we identified 
142 methylated peptides within the LDC. Of these, 124 methyl-peptides were also SILAC-
quantified (Fig. 20A, appendix 2) and the majority (118) contained methylated arginine. 
Overall, the „reverse‟ experiment led to a lower rate of methyl-peptides identification, 
probably as a consequence of a less efficient enrichment of the proteins of the complex in 
the co-IPs. However, the quantitation of methylated peptides identified was reproducible 
between the „forward‟ and the „reverse‟ experiments. Moreover, the observation that the 
amount of methyl-peptides identified on the LDC in the IPs is sensibly higher than in the 
input, confirms that the immuno-affinity enrichment strategy does efficiently increase the 
methyl-sites identification within a set of proteins of interest (Fig. 20A).  
Out of the quantified 124 methyl-peptides, almost 70% (86) resulted significantly regulated 
upon PRMT1 depletion (after statistical analysis described in Materials and Methods, 
paragraph 6.2), with the majority (76) containing R methyl-sites. Regulated peptides occur 
on 13 of the 23 subunits of the complex. On these peptides, we identified 97 different 
modifications on 80 distinct sites (Fig. 20B, upper panel); of note the number of peptides 
and sites does not coincide, since we identified more than one form of the same peptide 
bearing the same site. Among the 76 regulated R methyl-peptides, 46% were already 
annotated in the internal hmSILAC reference library (Fig. 20B, lower panel). Moreover, 
studying the sites identified on the regulated peptides, the 67% was reported in the library 
and therefore considered true and confident in vivo methyl-sites. The majority of them (46) 
occurred on arginine residues within 10 different subunits of the LDC, of which just FUS, 
TAF15, EWSR1 and ILF3 were already reported as PRMT1 targets, while DDX5, DDX17, 
ILF2, NCL and HNRNPH1 might represent newly identified substrates of the enzyme. 
Overall, we cannot extrapolate a clear trend of regulation of the methyl-peptides as we 
observe equal proportion of down- and up-regulated peptides. However, it is interesting 
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that in various cases, the same peptide is down-regulated when di-methylated and up-
regulated when mono-methylated (the peptides 465-
GMPPPLR(me)/(di)GGPGGPGGPGGPMGR-486 of EWSR1 and 602-
RAPVPVR(me)/(di)GGPK-613 of ILF3 are representative cases (Fig. 20A). This trend is 
in line with the type-I enzymatic activity of PRMT1, which asymmetrically di-methylates 
either unmodified or mono-methylated arginines. Noteworthy, this result also confirms 
previous experimental evidence showing that loss of PRMT1 caused a global decrease of 
arginine di-methylation, with a corresponding increase of R-mono-methylation [139]. 
A localization analysis showed that the majority of the sites identified on regulated 
peptides occurred within LC regions of the proteins, with a subset (21%) located in close 
proximity to RNA recognition Motifs (RRM) or to double strand RNA-binding Motifs 
(DSRM) (Fig. 20C). This suggests a potential regulatory effect of methylation in the 
binding of the complex to RNA, possibly newly processed microRNAs. 
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Fig. 20 Large Drosha Complex methyl-peptides changes upon PRMT1 depletion 
A) Heatmap display of log2 H/L ratio of identified methyl-peptides in input and IP samples 
of the „forward‟ and „reverse‟ experiments (red = high ratio; blue = low ratio). Green arrows 
indicate the mono- and di-methylated forms of the peptide 465-
GMPPPLRGGPGGPGGPGGPMGR-486 of EWSR1; light blue arrows indicate the mono- 
and di-methylated forms of the peptide 602-RAPVPVRGGPK-613 of ILF3. B) Summary of 
the regulated methyl-peptides identified on the LDC upon PRMT1 KD and summary of the 
hmSILAC library used as a reference (upper panel). Comparison of the results obtained 
with the hmSILAC library (lower panel). C) Pfam localization analysis of the methylated 
sites identified on regulated peptides (LC = Low Complexity regions; RRM = RNA 
Recognition Motifs; DSRM = Double Strand RNA-binding Motifs).  
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5.3.2 Validation of some PRMT1-specific targets on the complex through PRMT1 
overexpression  
Although the results obtained suggested that PRMT1 is responsible for the methylation of 
several components of the LDC, we could not exclude the possibility that other PRMTs 
could compensate to the loss of the enzyme. To validate the PRMT1-specific targets 
identified on the LDC, limiting the possible compensation by after overexpression of 
PRMT1.  
The scheme of the experiment is outlined in Figure 21A: HeLa were grown in light and 
heavy SILAC media up to full incorporation of light and heavy amino acids, respectively. A 
„forward‟ experiment was carried out, in which the light cells were infected with the empty 
vector (control) and the heavy-labeled ones with the construct for PRMT1 overexpression. 
Control and PRMT1-overexpressing cells were harvested, mixed 1:1 and separated into 
nuclear and cytoplasmic fractions (Fig. 21B, upper panel). Nuclear extract was either 
directly MS analyzed, or used as input for the immuno-affinity enrichment of the complex 
through DGCR8, DDX5 and FUS IPs (Fig. 21B, lower panel). The immunoprecipitated 
material in the three IPs and the nuclear input were separated by SDS-page; nine slices 
for gel lane were excised and subjected to trypsin digestion, followed by MS analysis with 
a Q Exactive instrument. MS data were processed with MaxQuant for protein identification 
and quantification of unmodified and methylated peptides. The IP experiments performed 
led to an overall efficient enrichment of the complex compared to background (Fig. 21C).  
We defined proteins that were significantly up-/down-regulated by PRMT1 
overexpression, based on the distribution of log2 SILAC H/L ratios for all proteins identified 
in the nuclear input considering  ± 2Fig. 21D): as expected, PRMT1 (marked in red) is 
significantly up-regulated, while the expression of the LDC subunits (green population 
centered on zero) is not significantly affected.  
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Fig. 21 SILAC/co-IP approach for the validation of PRMT1-specific targets on the 
Large Drosha Complex 
A) Workflow of the experimental strategy: the „forward‟ experiment is represented. B) 
Upper panel: WB analysis of PRMT1 overexpression and WB evaluation of cell 
fractionation; VCL was used as loading control; VCL and Histone H3 (H3) were used as 
marker for cytoplasm and nucleus respectively. Lower panel: WB validation of DDX5, 
DGCR8 and FUS IPs. IgG-IP was used as negative control. C) Coomassie-stained gel of 
DDX5, DGCR8, FUS and IgG IPs. Dashed lines indicate the slices in which each lane was 
cut for protein in-gel digestion and peptide extraction prior to LC-MS/MS. D) Evaluation of 
the efficiency of each IP in the enrichment of the complex. For each IP experiment the 
iBAQ intensities of the proteins of the complex in the light (control) sample were compared 
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to those of the background proteins. E) Log2 H/L ratio distribution of nuclear proteins 
identified in the „forward‟ experiment (in blue), upon PRMT1 overexpression. Dashed grey 
lines indicate the cut off to define significantly regulated proteins ( ± 2mean ± 2 
standard deviations). LDC components are highlighted in green; the red arrow highlights 
the position of PRMT1 within the distribution.  
 
We identified and quantified a total of 80 methyl-peptides within the LDC, 67 of them 
(84%) containing R-methyl-sites. They occur on 14 proteins of the complex and within 
these peptides, we identified 91 methyl-sites bearing 103 different modifications 
(Fig.22A, left panel). Comparing these results with the hmSILAC library, we noticed that 
just the 36% of R-containing methyl-peptides and the 49% of the methyl-sites identified 
was already annotated (Fig. 22A, right panel). This limited overalap is somehow 
unexpected. A possible explanation could lie in the fact that in both the endogenous and 
ectopic PRMT1 are expressed and active in this experiment, leading to an increased 
cellular R-methylation on protein/sites that are not modified (and therefore not reported in 
the library) at the basal state.  
The overexpression experiment was set up with the aim of validating PRMT1 targets 
identified in the previous depletion experiment, circumventing the compensation caused 
by other PRMTs when PRMT1 is down-regulated. Hence, we directly compared all the 
methyl-peptides identified in both experiments and found 42 methyl-peptides in common, 
occurring on 11 proteins of the complex (Fig. 22B, appendix 3). Several methyl-peptides 
show a specular trend between PRMT1 depletion and overexpression: for instance, the 
mono-methylated peptide 465-GMPPPLR(me)GGPGGPGGPGGPMGR-486 of EWSR1 
(indicated by the upper green arrow) is up-regulated upon PRMT1 KD and down-
regulated when the enzyme is overexpressed. Interestingly, its di-methylated version 
(lower green arrow) behaves in the opposite way, being down-regulated upon the 
enzyme depletion and slightly up-regulated after the increase of PRMT1. These results 
are in line with the enzymatic activity of PRMT1 and with previous evidence [139], 
confirming that these specific methyl-peptides are real novel experimental PRMT1 
targets.  
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However, we also observed cases where the peptides do not display opposite trend of 
methylation between the depletion and overexpression experiments: for instance some 
peptides are strongly down-regulated upon KD but not up-regulated when PRMT1 is 
induced (light blue line in Fig. 22B). This could be due to the fact that peptides are 
methylated at the basal level by the endogenous PRMT1 at saturation, thus cannot be 
further modified by the ectopic enzyme, thus producing “non-changing” ratios.   
Considering these data (and taking into account that the „reverse‟ experiment of PRMT1 
overexpression is still on-going), we were able to confirm the identification of a number of 
PRMT1 targets of the LDC, which are listed in Fig. 22C. We excluded from the analysis 
those methyl-peptides that were non-regulated in both experiments and those that 
contained K methyl-sites. Only FUS, TAF15 and ILF3 were already reported as PRMT1 
targets, even though for none the specific methyl-sites had been specified before, while 
all the remaining represents novel PRMT1 substrate annotations. The new PRMT1 target 
sites identified occur mainly in LC/disordered regions, corroborating the hypothesis that 
methylation may be functionally important to mediate protein-protein or protein-RNA 
interactions.  
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Fig. 22 Profiling of the Large Drosha Complex methyl-peptides changes after 
PRMT1 overexpression 
A) Summary of the regulated methyl-peptides identified on the LDC upon PRMT1 
overexpression and summary of the hmSILAC library as a reference (left panel). 
Comparison of the results obtained with the hmSILAC library (right panel). B) Heatmap of 
log2 H/L ratio of methyl-peptides commonly identified in the PRMT1 depletion and 
overexpression experiments (red = high ratio; blue = low ratio). Ratios reported are the 
average ratios of input, DGCR8 IP, DDX5 IP and FUS IP for each experiment. Green 
arrows indicate the mono- and di-methylated forms of the peptide 465-
GMPPPLRGGPGGPGGPGGPMGR-486 of EWSR1. Light Blue line indicates cases in 
which peptides were down-regulated in the KD experiment, while were not regulated in 
the overexpression one. In cases of ambiguously localized methylations on the same 
peptide, both possible forms of the methyl-peptide are reported. C) Summary table of 
PRMT1 targets identified in this study. Already known targets are reported. Protein 
domains in which identified methyl-peptides occur are reported for each target (LC = Low 
Complexity; DSRM = Double Strand RNA-binding Motifs) 
 
5.4 Study of the impact of PRMT1-mediated methylation on miRNA biogenesis 
The results obtained from the LDC methylation analysis confirmed that R-methylation 
frequently occurs on the complex and that several methyl-sites on specific subunits are 
modified by PRMT1.  In fact, the modulation of its expression causes alteration in the 
methylation state of the LDC. Hence, we explored the possibility that methylation of the 
complex could regulate its function, with a direct impact on miRNA biogenesis.  
 
5.4.1 The effect of PRMT1 depletion on the expression of miRNAs 
We profiled by quantitative PCR (qPCR) analysis the effect of PRMT1 on the expression 
of a panel of miRNAs for which previous studies have reported both a crucial role in 
cancer [155] [156] and a deregulation upon  the knock down of some LDC subunits [23, 
157, 158]. Specifically, we studied the miRNAs from the miR-15a/16-1 cluster (which 
includes miR-15a and miR-16-1), the miR-17/92 cluster (that comprises miR-17, miR-18, 
miR-20, miR-19a, miR-19b and miR-92) and miR-150.  
In the previous proteomic experiments, we compared the R-methylation changes between 
PRTM1 KD and control cells, the latter being generated by cell transduction with lentiviral 
particles carrying the pLKO.1 empty vector, which did not generate any sh-RNA. 
Importantly, the processing of exogenous sh-RNAs could saturate the RNAi cellular 
machinery regardless of their sequences, ultimately impinging on the synthesis of 
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endogenous miRNAs. We thus profiled the expression levels of a panel of miRNAs upon 
cell transduction with lentiviral particles carrying different sh-RNA sequences not targeting 
PRMT1. We tested the empty vector, a scramble sh-RNA (Scr) which sequence is not 
specific for any gene, a sh-RNA specific for the Luciferase gene (Luc) and, as further 
control, we tested also lentiviral particles not carrying any sh-RNA (empty lentiviral 
particles).  
Cells were collected after 96h from infection and miRNAs were isolated. qPCR profiling 
showed that miRNA expression was comparable when cells were transduced with empty 
vector, Scr and with empty lentiviral particles, while significantly decreased when using 
sh-Luc (Fig. 23A). Hence, we excluded this last construct from the analysis. In parallel the 
WB profiling of PRMT1 protein level indicated that PRMT1 is slightly but reproducibly 
increased when using the scramble construct (Fig. 23B). On the basis of these results, we 
chose the empty vector as negative control for all subsequent analyses.  
We also carefully optimized the infection protocol of HeLa cells paying specific attention to 
the cell confluence. miRNA expression is tightly regulated by cell to cell contacts and 
when cells reach confluence, their expression is enhanced in the confluent cells compared 
to the proliferating ones [25, 159]. As a matter of fact, HeLa growth was not affected by 
the PRMT1 KD within the 0-96h time window (Fig. 16B, left panel), and when cells reach 
confluence, a significant difference of miRNA expression between confluent and non-
confluent cells was observed (Fig. 23C). Hence, we introduced in our protocol a cell 
dilution step at 24h post infection, in order to avoid cell confluence while profiling 
methylation changes and miRNA expression in the 72-96h post infection time window.  
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Fig. 23 Optimization of PRMT1 KD protocol for miRNA expression profiling 
A) Selection of the best negative control: qPCR analysis of miR-16 and miR-19b 
(representative for miR-15a/16-1 and miR-17/92 clusters) upon lentiviral infection with 
different constructs (Empty = empty vector; Scr = sh-scramble; Luc = sh-Luciferase; Virus 
= lentiviral particles not carrying any sh-RNA). DGCR8 used for data normalization. B) 
WB analysis of PRMT1 level upon infection with sh-B6, sh-B10 and with the different 
negative control constructs (Empty, Scr, Luc); WT = HeLa wild-type. VCL was used as 
loading control. C) qPCR analysis of miR-16 expression in non-confluent and confluent 
cells upon PRMT1 depletion. DGCR8 was used for data normalization. 
 
We then profiled the expression of mature miRNAs of the miR-15a/16-1 and miR-17/92 
clusters upon PRMT1 KD, in a time window between 24 and 96 hours after the infection. 
A reduction of miRNAs levels occurred between 72 and 96h post infection (Fig. 24A), with 
a striking decrease at 72h. Since we also observed changes in the LDC methylation state 
in this time frame, we decide to focus on this time point for further analysis, which 
confirmed that PRMT1 depletion induces significant down-regulation of all miRNAs 
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analyzed, with the exception of miR-150 (Fig. 24B), which was selected as negative 
control in subsequent assays.  
 
 
 
Fig. 24 PRMT1 depletion causes down-regulation of mature miRNA expression 
A) Time-course expression profiling by qPCR of a subset of miRNAs upon PRMT1 KD 
with sh-B6 and sh-B10. Histograms represent mean ± SEM (n=2). DGCR8 was used for 
data normalization. B) qPCR profiling of miRNA upon PRMT1 depletion (72h PI) with sh-
B6 and sh-B10. DGCR8 was used for data normalization. Histograms represent mean ± 
SEM (sh-B6: n=4, t-Test: equal variances, two-tail, * = p≤0.05, **=p≤0.01, ***≤0.001; sh-
B10: n=2). 
 
5.4.2 Global miRNA expression analysis  
To assess the general effect of PRMT1 depletion on miRNA biogenesis, we initially 
performed a global study of miRNA expression using TaqMan Array Human microRNA 
cards. We profiled 600 miRNAs, 172 of which were robustly quantified in both control and 
PRMT1 KD cells (Fig. 25A). The expression of 34 miRNAs was completely suppressed 
upon PRMT1 KD, while 72 were significantly down-regulated (fold change < 1.5). The 
results obtained for miR-17/92, miR-15a/16-1 and miR-150 expression were in line with 
the qPCR analysis, confirming the down-regulation of the miRNAs from the two clusters, 
while miR-150 was unaffected (Fig. 25B). This analysis extends the result achieved by 
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qPCR and shows that PRMT1 is crucial for the correct miRNA biogenesis, as its depletion 
causes a general deregulation of miRNAs levels, with several significantly down-regulated 
miRNAs and a minor fraction of up-regulated miRNAs. 
 
 
 
Fig. 25 PRMT1 depletion causes a general deregulation of mature miRNA expression 
A) Global expression analysis of miRNAs upon PRMT1 KD (sh-B6) performed with 
TaqMan Array Human miRNA Cards. Data were normalized on the geometric mean of a 
panel of housekeeping genes (mammU6, RNU44, RNU46, U6snRNA). Histograms 
represent mean ± SEM of miRNAs identified and quantified in two technical replicates. 
Significantly regulated up/down-regulated miRNAs considered when greater/lower than 
1.5 fold changes. B) Table reporting the expression of miRNA of the miR-15a/16-1 and 
miR-17/92 clusters and miR-150 in the TaqMan card analysis. The average log2 ratio of 
two technical replicates is reported. ND = Not Detected. 
 
We then took advantage of Small-RNA Sequencing to further extend and strengthen this 
global analysis, using the two sh-RNA constructs available for PRMT1 depletion, in two 
independent biological replicates. 
We observed an overall reduction in the number of reads corresponding to canonical 
miRNAs in the samples with PRMT1 depletion, compared to controls (Fig. 26A, upper 
panel), suggesting a global unbalance in miRNA expression. Interestingly, the analysis of 
small nucleolar RNA (snoRNA) showed a comparable amount of the reads among 
samples, confirming that the effect of PRMT1 depletion is specific for miRNA processing 
(Fig. 26A, lower panel). In fact, snoRNAs are small non-coding RNAs that function as a 
guide for the chemical modification of ribosomal RNA and are independent from the 
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Drosha processing pathway [147]. Since snoRNA were not affected by the knock down of 
PRMT1, we used them as normalizers for the data. 
The expression of the majority of the 225 miRNAs detected in control and PRMT1-
depleted cells was reduced after the KD with both sh-RNAs, in the two biological 
replicates, with 41 miRNAs significantly down-regulated (Fig. 26B, left panel). Only a 
small subset of miRNAs was not affected or slightly increased by the PRMT1 KD. Among 
the down-regulated miRNAs we identified several miRNAs from the cluster miR-15a/16-1 
and miR-17/92, confirming the results from qPCR and miRNA array (Fig. 26B, right 
panel). Moreover, the small-RNA sequencing allowed a more in-depth analysis, 
investigating the effect of PRMT1 on the processing of miRNAs of different origin. 
MicroRNAs are generally classified as “intergenic” or “intronic” based on their genomic 
location.  Intronic miRNAs derive from the processing of introns and require spliceosomal 
components for their biogenesis [160] [161]. Interestingly, we did not observed any 
differential effect of PRMT1 KD between intronic and intergenic miRNAs (Fig. 26C, upper 
panel), suggesting that they are all equally affected. In addition, we analyzed the effect of 
PRMT1 on Drosha cleavage. In fact, miRNAs can originate from the 5‟ (5p) or 3‟ (3p) arm 
of the hairpin, depending on Drosha activity, and an error in the cleavage could alter the 
relative stability of the two strands, resulting in the incorporation of the improper miRNA 
strand into the RISC complex [162]. However, the observation that 5p and 3p miRNAs are 
equally regulated suggests that PRMT1 depletion does not have a direct impact on 
Drosha cleavage (Fig. 26C, lower panel).  
Overall, these global studies of miRNA expression indicate that PRMT1 is fundamental for 
the correct biogenesis of miRNAs, as its depletion causes their massive down-regulation, 
even if it does not directly affect Drosha cleavage efficiency. 
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Fig. 26 PRMT1 depletion causes global down-regulation of mature miRNA 
expression 
Global miRNA expression analysis by Small-RNA sequencing. A) Upper panel: 
histograms representing the number of reads corresponding to canonical miRNAs in 
control (Empty 1-2) and PRMT1 knock down (sh-B6 1-2, sh-B10 1-2) samples. Lower 
panel: histogram representing the number of reads corresponding to snoRNAs in control 
(Empty 1-2) and PRMT1 knock down (sh-B6 1-2, sh-B10 1-2) samples. The experiment 
was performed using two biological replicates (1-2); PRMT1 KD was obtained with two sh-
RNAs (sh-B6, sh-B10). B) Left panel: the heatmap shows log2 fold change of miRNAs 
identified in control (Empty) and PRMT1 KD (n = 225); (red = high fold change; green = 
low fold change). Data are the average of two independent biological replicates. Red lines 
indicate significantly down-regulated miRNAs (41); (t-Test: equal variances, two-tail, * = p-
value < 0.05). Right panel: table reporting the expression of miRNA of the cluster miR-
15a/16-1 and miR-17/92 detected by Small-RNA sequencing. Log2 fold change of the 
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average of the two sh-RNAs is reported (* = p-value < 0.05). C) Upper panel: box plot 
show the distributions of intergenic and intronic miRNAs upon PRMT1 KD. Data are the 
average of the two independent biological replicates using both sh-B6 and sh-B10. Data 
were normalized on miRNAs RPM. Lower panel: box plot show the distributions of 5p (n = 
79) and 3p (n = 60) miRNAs upon PRMT1 KD. Data are the average of the two 
independent biological replicates using both sh-B6 and sh-B10. Data were normalized on 
miRNAs RPM. 
 
5.4.3 Primary and precursor miRNA analysis upon the depletion of PRMT1   
Encouraged by the evidence that PRMT1 depletion affects miRNA expression, we 
hypothesized that the altered methylation state of the Large Drosha Complex caused by 
PRMT1 down-regulation may affect the processing step of primary- to precursor- miRNAs 
catalyzed by the complex, thus altering the relative ratio of pri- to pre- levels.  The ultimate 
effect would be measured as a reduction of mature miRNAs (Fig. 27A). Therefore, we 
looked more specifically at the effect of PRMT1 depletion on this processing step and 
designed specific qPCR primers that allow profiling the different miRNA intermediates of 
miR-15a/16-1 and miR-17/92 and that are described in the Materials and Methods 
section, paragraph 4.11.  
We did not observe significant changes in the primary transcript levels upon PRMT1 KD 
with both sh-RNAs (Fig. 27B). However, interestingly, we found a significant and 
reproducible down-regulation of several pre-miRNAs (Fig. 27C). These results confirm 
that the depletion of PRMT1 not only reduces mature miRNA expression but also affects 
the pri-to-pre miRNA processing step. In addition, the observation that the expression of 
the primary transcripts is not diminished but rather slightly increased excludes the 
possibility that the reduction of pre-miRNAs may be a consequence of the effect of 
PRMT1 depletion on pri-miRNAs transcription. The slight increase of pri-miRNAs could 
reflect the accumulation of the un-processed primary transcripts due to the impairment of 
the LDC-mediated processing (Fig. 27A). 
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Fig. 27 The processing of primary to precursor miRNAs is impaired by PRMT1 
depletion 
A) Schematic representation of miRNA biogenesis and hypothesized PRMT1 role within 
this process. When the LDC-methylation is unaffected, pri-miRNAs are normally 
processed to pre-miRNAs (upper panel). When the LDC methylation pattern is altered, the 
pri- to pre-miRNA processing is impaired and pre- and mature miRNAs levels are reduced 
(lower panel). B) qPCR profiling of the pri-miRNAs of the clusters miR-15a/16-1 and miR-
17/92 upon PRMT1 KD with sh-B6 and sh-B10. DGCR8 was used for the normalization of 
the data. Histograms represent mean ± SEM (n =3; t-Test, equal variances, two-tail, * = 
p≤0.05, **=p≤0.01, ***≤0.001). C) qPCR profiling of the pre-miRNAs of the clusters miR-
15a/16-1 and miR-17/92 upon PRMT1 KD with sh-B6 and sh-B10. DGCR8 was used for 
the normalization of the data. Histograms represent mean ± SEM (sh-B6: n=4: t-Test, 
equal variances, two-tail, * = p≤0.05, **=p≤0.01, ***≤0.001. sh-B10: n=2). 
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We focused on the cell compartment where the processing step of the miRNA biogenesis 
catalyzed by the LDC occurs, to further confirm that the activity of the complex is impaired 
in the absence of PRMT1. Therefore, we analyzed each miRNA intermediate product in 
the different cellular compartments, namely cytosol, nucleosol and chromatin fraction. The 
same amount of control and PRMT1-depleted cells was subjected in parallel to total cell 
lysis or to sub-cellular fractionation (Fig. 28A). Total RNA (including miRNAs) was then 
extracted from all samples. Pri-, pre- and mature miRNAs of the clusters miR-15a/16-1 
and miR-17/92 were isolated from the total extract and profiled by qPCR, confirming the 
accumulation of the pri-miRNAs and the corresponding down-regulation of pre- and 
mature miRNAs upon PRMT1 depletion (Fig. 28B, left panel). We then focused on the 
pri- to pre- processing step in the nuclear fraction, which is the compartment where the 
LDC is active. We profiled pri-miRNAs in the chromatin fraction, where they are firstly 
located being transcribed by RNA polymerase II. Subsequently the pri-miRNAs are 
processed by the LDC into pre-miRNAs, which are exported from the nucleosol into 
cytoplasm, where they undergo further processing. We observed a 10% increase of pri-
miRNAs in the chromatin fraction upon PRMT1 KD (Fig. 28B, right panel), corroborating 
the hypothesis that the depletion of the enzyme correlates with the impairment of the 
processing. In line with this observation, we observed decreased pre-miRNAs level in the 
nucleosol, followed by a slight increase of their levels in the cytoplasm (Fig. 28B, right 
panel). This result led us to speculate that, when the processing is impaired, the export in 
the cytoplasm of residual pre-miRNAs might be favored.   
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Fig. 28 Pri-, pre- and mature- miRNA analysis in specific cell compartments  
A) WB validation of the efficiency of cell fractionation into cytosolic (Cyto.), nucleosolic 
(Nucl.) and chromatin (Chrom.) fractions in control and PRMT1 KD cells. VCL and Lamin 
B were used as cytosolic and chromatin markers, respectively. B) Left panel: qPCR 
analysis of pri-, pre- and mature miR-15a (representative of all miRNAs analyzed) in total 
cell extract from control (Empty) and PRMT1-depleted cells (sh-B6). Absolute expression 
of each miRNA form is reported. Right panel: qPCR analysis of pri- and pre-miR-15a in 
specific cell compartments in control (Empty) and PRMT1-depleted cells (sh-B6). The 
percentage of pri- and pre-miR-15a normalized on their total amount in all cell 
compartments is reported.  
 
5.5 Investigation of the molecular mechanisms linking protein methylation to 
altered miRNA biogenesis 
Protein methylation regulates several aspects of cellular homeostasis, essentially through 
three mechanisms: either altering protein sub-cellular localization, or modulating protein-
protein and protein-nucleic acid interactions [46, 163]. We took into account all these 
mechanisms to try to dissect the molecular link between PRMT1-regulated arginine 
methylation on the LDC and altered miRNA biogenesis.  
 
5.5.1 Analysis of the sub-cellular localization of Large Drosha Complex subunits in 
the absence of PRMT1 
We performed a WB analysis of the sub-cellular localization of several LDC components 
upon PRMT1 depletion, to assess whether we could detect changes in their subcellular 
distribution. None of the subunits tested show significant changes in their localization in 
the KD sample, compared to control (Fig. 29), which indicated that the absence of PRMT1 
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and the related changes in methylation do not affect the cellular distribution of the majority 
of the LDC components, at least the one profiled by WB.  
 
 
 
Fig. 29 The absence of PRMT1 does not affect the cellular distribution of several 
subunits of the LDC 
WB analysis of the sub-cellular localization of the LDC proteins, in control (Empty) and 
PRMT1 KD (sh-B6) cells. VCL and GAPDH were used as cytosolic marker; Lamin B and 
H3 were used as nuclear markers. Increasing amounts of extracts (10 and 20 g) were 
used.  
 
5.5.2 The role of methylation in the regulation of protein-RNA or protein-protein 
interactions 
The interaction among DGCR8 and Drosha, the core components of the Large Drosha 
Complex, occurs through a direct protein-protein contact [18], while the binding of other 
subunits of the complex with the Microprocessor can be mediated both by RNA [17] or by 
protein-protein interaction [164]. However, a comprehensive study of how accessory 
proteins associate to the Microprocessor within the LDC is still absent. 
To understand whether RNA mediates interactions within the complex, we performed LDC 
immunoprecipitation using DCGR8 as bait, starting from nuclear extracts treated or not 
with RNase A. The binding of several components was profiled by WB analysis. The 
efficiency of the affinity-purification of DGCR8 was not affected by RNase A treatment 
(Fig. 30A, left panel) as well as the DGCR8/Drosha interaction, as expected. Moreover, 
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we did not observe relevant changes in the interaction of other subunits, such as DDX17, 
DDX5 and ILF2, with the bait; from this we can conclude that their interaction with the 
Microprocessor is not mediated by RNA (Fig. 30A, right panel). 
However, it is known that RNA mediates the interaction of DGCR8/Drosha with some LDC 
components such as Nucleolin [17]. Thus, to extend the analysis also to subunits which 
interaction was not assessed by WB, we are performing the proteomic experiment 
illustrated in Fig. 30B. We labeled wild-type (WT) HeLa in standard heavy and light SILAC 
media, up to full incorporation. Heavy and light cells were harvested, separated into 
nuclear and cytosolic fractions and the heavy-labeled nuclear extract was treated with 
RNase A, while the light-labeled one was left untreated, in a „forward‟ experimental setup. 
We performed two DGCR8 IPs in parallel, using both RNase A-treated and untreated 
extracts as input. The immunoprecipitated samples were then mixed 1:1, analyzed by 
geLC-MS/MS and raw data analyzed by MaxQuant software, as described in Materials 
and Methods (paragraph 4.6). Within this experimental setup, proteins whose interaction 
with DGCR8 is RNA mediated will show a decreased H/L SILAC ratio, while interactions 
that are not affected by the treatment will produce H/L ratio equal 1.  If we will discover 
that the interaction of some subunit is RNA-mediated, we plan to setup experiments, 
which will allow assessing whether the modulation of R-methylation on specific subunits 
might affect their recruitment on the complex.  
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Fig. 30 Analysis of the role of RNA in modulating the interactions among subunits 
of the LDC 
A) Immunoprecipitation of DGCR8 (indicated in red) from nuclear extracts treated or not 
with RNAse A, followed by WB analysis. FT = Flow-through. B) Workflow of the SILAC-
based proteomic experiment: the „forward‟ experiment is represented. Upon LC-MS/MS 
analysis, a decreased H/L ratio indicates a loss of the interaction (RNA-mediated); 
unchanging H/L ratios represent proteins whose interaction with DGCR8 is not affected 
by the loss of RNA (not RNA-mediated). 
 
Based on the observation that methyl-sites that are regulated by PRMT1 occur mainly 
within LC/disordered regions of various LDC subunits (Fig. 20C and Fig. 22C), we 
evaluated whether R-methylation affects protein-protein interactions within the complex. 
We performed DGCR8 IPs starting from nuclear extracts of PRMT1-depleted and control 
cells, followed by WB analysis. The amount of immunoprecipitated DCGR8 was 
comparable in the two functional states. However, the co-immunoprecipiation of other 
subunits known to directly interact with DGCR8, such as DDX17, DDX5 and ILF3 [19, 
165], was altered upon PRMT1 knock down (Fig.  31A), suggesting that the modulation 
of methylation exerted by the enzyme depletion may influence the interaction among 
proteins of the complex. We extended this analysis to the whole complex by performing a 
SILAC-based proteomic experiment, which is also ongoing (Fig. 31B). We labeled HeLa 
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by growing them in standard SILAC media. Upon full incorporation, cells were infected 
with either the empty vector or with sh-B6, harvested and fractionated in nuclear and 
cytosolic fractions. We performed in parallel DGCR8 IPs starting either from control or 
PRMT1-depleted nuclear extracts. The immunoprecipitated materials were then mixed in 
equal amount (1:1), analyzed by geLC-MS/MS and raw data analyzed by MaxQuant 
software, as described in Materials and Methods (paragraph 4.6). Alterations in the H/L 
SILAC ratio of the proteins of the LDC will reflect changes in their interaction with DGCR8 
in the absence of PRMT1.   
 
 
 
Fig. 31 Study of the role of methylation in the regulation of protein-protein 
interactions within the LDC 
A) Immunoprecipitation of DGCR8 (indicated in red) from nuclear extracts of control 
(empty) and PRMT1-depleted (sh-B6) cells, followed by WB analysis. The co-IP of DDX17 
and DDX5 was also assessed. FT = Flow-through; IgG IP was used as negative control. 
B) Workflow of the SILAC-based proteomic experiment: the „forward‟ experiment is 
represented. Upon LC-MS/MS analysis, an increased H/L ratio indicates proteins that are 
recruited to DGCR8 upon PRMT1 KD; decreased H/L ratios indicates a loss of the 
interaction (evicted); unchanging H/L ratios represent proteins whose interaction with 
DGCR8 is not affected by the loss of PRMT1.  
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Based on the results of the proteomic experiments we are performing, we will have 
insights on how the accessory proteins of the LDC interact with each other and/or with the 
Microprocessor, and how R-methylation may regulate the structure of the Large Drosha 
Complex, ultimately impacting on its activity.  
 
5.6 Impact of other PRMTs on miRNA biogenesis 
The PRMTs family comprises several enzymes besides PRMT1, thus we wanted to 
investigate if they might also play a role in the regulation of miRNA biogenesis. 
In parallel to the set up of KD and overexpression protocols to modulate PRMT1 
expression, we established protocols to deplete other important PRMTs, such as PRMT4, 
PRMT6, PRMT5 and PRMT7. For each enzyme we tested two different sh-RNA 
sequences, which were all efficient in depleting the respective target, except for PRMT5 
sh-446 (Fig. 32A). Given the crucial role of PRMTs in the regulation of cell cycle [50, 166] 
we studied cell growth after the depletion of each individual enzyme, in a time window 
between 4 and 8 days post infection. Similarly to the results obtained upon PRMT1 KD, 
we observed that the depletion of PRMT4, PRMT6 and PRMT7 strongly reduces cell 
viability starting from 4 days after the infection, while PRMT5 knock down results in a less 
prominent reduction (Fig. 32B). We then profiled global methylation changes in the same 
time window, by WB analysis of total extract, using anti pan-methyl antibodies that 
recognize asymmetric (ASYM24) or symmetric (SYM10) di-methylation: in fact, PRMT4 
and PRMT6 catalyze asymmetric di-methylation and PRMT5 and PRMT7 asymmetric di-
methylation of their targets [50]. Four days upon infection, all enzymes are completely 
depleted (except with PRMT5 sh-446), and changes in di-methylations compared to 
control cells are clearly detectable (Fig. 32C).  
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Fig. 32 Set up of the knock down of other PRMTs 
A) WB analysis of PRMT4, PRMT5, PRMT6 and PRMT7 expression upon their depletion 
using two sh-RNA sequences per protein (PRMT4: sh-A2, sh-A4; PRMT5: sh-446, sh-
447; PRMT6: sh-A7, sh-D10; PRMT7: sh-A11, sh-A12). Empty vector was used as 
negative control. VCL was used as loading control. B) Growth curves of control and 
PRMTs-depleted cells between 4 and 8 days PI. C) Time course profiling of PRMTs 
depletion and asymmetric (asym24) and symmetric (sym10) di-methylation between 4 and 
8 days PI. VCL was used as loading control. Red asterisks highlight changes in di-
methylation. 
 
Starting from the evidence that changes in global protein methylation is observed when 
most PRMTs are depleted, we asked whether their depletion affects also miRNA 
biogenesis in a similar manner and to a similar extent as PRMT1. We profiled the 
expression of the miRNAs of miR-15a/16-1, miR-17/92 clusters and of miR-150 by qPCR 
and observed a reduction of mature miRNAs 72h after PRMT1 depletion, paralleled by the 
accumulation of their corresponding pri-miRNAs. However, the effect of PRMT4, PRMT5 
and PRMT7 depletion on the expression of both primary and mature miRNAs is not similar 
to that of PRMT1, at least to the subset of miRNAs tested (Fig. 33A), and the few 
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changes observed may be miRNA- or PRMT- specific. However, we observed a 
significant down-regulation of all mature miRNAs analyzed upon PRMT6 depletion using 
both sh-RNAs (Fig. 33B). PRMT6 is an important transcriptional regulator, acting as either 
co-activator or repressor depending on the different R-sites that methylates (H3R42me2a 
and H3R2me2a, respectively) [76, 77, 80]. Therefore, we focused on the analysis of the 
expression levels of pri-miRNAs in order to evaluate whether the effect on mature 
miRNAs may be due to transcriptional inhibition rather than an impairment of LDC 
function. Pri-miR-15a/16-1 and pri-miR-17/92 were slightly down-regulated upon PRMT6 
KD (Fig. 33C), suggesting that this enzyme might have an impact on the primary miRNAs 
transcription. Yet, these results do not exclude that also PRMT6 might affect miRNA 
biogenesis altering the methylation state of the LDC.  
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Fig. 33 qPCR analysis of miRNAs upon the KD of other PRMTs  
A) qPCR analysis of pri- and mature miR-15a (representative of all the miRNAs analyzed) 
upon PRMT1, PRMT4, PRMT5 and PRMT7 KD. DGCR8 was used for data normalization. 
B) qPCR analysis of mature miRNAs of the clusters miR-15a/16-1 and miR-17/92 and 
miR-150, upon PRMT6 KD with sh-A7 and sh-D10. DGCR8 was used for data 
normalization. C) qPCR analysis of pri-miR-15a/16-1 and pri-miR-17/92, upon PRMT6 KD 
with sh-A7 and sh-D10. DGCR8 was used for data normalization. 
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6. DISCUSSION 
 
In this study, we employed MS-based proteomics to investigate the role of arginine 
methylation in regulating the activity of the Large Drosha Complex and consequently the 
process of miRNA biogenesis.  
We initially combined the hmSILAC approach with co-immunoprecipitations of the LDC to 
carry out a thorough characterization of un-ambiguously identified methylations occurring 
on the diverse components of the complex. We identified 90 different methylated sites on 
the complex, the majority of which occurs on arginine residues, confirming the highly 
methylated nature of the LDC.  
Almost all the subunits of the complex are modified, some of them on multiple sites. 
However, interestingly, the core components, DGCR8 and Drosha, are not. It has been 
reported that they interact with each other through a direct protein-protein interaction, and 
with the primary transcript through specific RNA Binding Domains (RBDs) (see 
Introduction, paragraph 2.1). However, this result suggests that methylation may affect the 
binding of the accessory subunits to the Microprocessor rather than the structure/activity 
of the Microprocessor itself, since it can regulate both protein-protein and protein-RNA 
interactions. 
In a very recent work from the Nielsen group, R-methylated sites have been identified on 
several protein complexes, including the LDC and other complexes involved in RNA 
metabolism [34]. On the Large Drosha complex, they identified methyl-sites on all the 
proteins of the complex, with the exception of DGCR8. However, in this study the authors 
did not use orthogonal validation approaches for high-confidence identification of 
methylated sites, such as hmSILAC or its variants. Thus, although the majority of the 
methyl-sites identified by Nielsen and colleagues has been characterized also by us, upon 
hmSILAC validation, the confidence of the remaining sites identified by them remains 
uncertain. Indeed, different groups have shown that label-free approaches are not ideal 
for global analysis of methylation, since they lead to high FDR in methyl-assignment [44, 
136]. Since the generation of robust and reliable data is fundamental for the subsequent 
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biological and functional studies, and, at present, the most efficient strategy to decrease 
the FDR in large-scale MS-based methylation analyses is the hmSILAC, we decided to 
exploit this strategy in our study. Hence, we built a library of confidently annotated methyl-
sites for the LDC and used it as a reference for the analysis of changes in the methylation 
state of the complex after modulation of PRMT1 expression.  
For this purpose, we combined SILAC with the affinity enrichment of the LDC. The 
observation that the amount of methyl-peptides identified after the enrichment of the 
complex is higher than in the input confirmed that the immuno-affinity enrichment strategy 
adopted is an efficient method for the characterization of methylations of proteins and 
complexes of interest. This result also highlights the importance of overcoming the sub-
stoichiometric nature of methylation by adopting efficient enrichment strategies prior to 
MS, as discussed in the Introduction (paragraph 2.6 and 2.6.2). Quantification analysis of 
asymmetric di-methylated arginine (ADMA), symmetric di-methylated arginine (SDMA) 
and mono-methylated arginine (MMA) at steady state, in MEFs, showed that ADMA is the 
predominant methylated arginine residue [138]. However, in the majority of the global 
proteomics studies mono-methylated arginine is the most represented modification. This 
result is likely due to the fact that these analyses are based on the specific enrichment of 
ADMA, SDMA and MMA peptides by antibodies that recognize the differently modified 
residues, and among them the MMA antibody has proven  to be the most efficient [132]. In 
our study we enriched the proteins of the LDC instead of the methylated peptides, and this 
leads to the annotation of an equal amount of ADMA and MMA at steady state (Fig. 14B) 
and also to the identification of more ADMA compared to MMA on regulated methyl-
peptides after PRMT1 depletion (Fig.20, appendix 2). These observations suggest that 
the co-IP approach allows overcoming possible biases introduced by the use of pan-
methyl antibodies.  
Comparing the PRMT1-regulated methyl-peptides identified after the depletion of the 
enzyme with the hmSILAC library, we found that the 67% of the methyl-sites (53) were 
already annotated. The sites not reported in the hmSILAC reference might be either false 
positive identifications or true methyl-sites, missed by the initial screening. Indeed 
 89 
 
drawbacks of shotgun proteomics are linked to its recognized bias towards high 
abundance peptides and to its stochastic nature that do not allow identifying all 
proteins/PTMs in a sample, in a single run. Considering that our library was built 
performing five different affinity enrichments of the complex, it is likely that some methyl-
sites were not detected in these experiments. Hence, the manual inspection at the MS/MS 
level of these modified peptides will be essential to understand whether they are true 
sites, or artifacts. 
The profiling of the methyl-proteome upon PRMT1 KD suggested that several subunits of 
the complex are PRMT1 targets and that the depletion of the enzyme causes changes in 
the methylation state of the LDC. However we cannot exclude the possibility that other 
PRMTs may compensate or compete for the loss of the major enzyme. Indeed, the 
depletion of PRMT1 seems to cause a complex response in terms of methylation changes 
on the LDC. Although on the one hand we observed the down-regulation of several mono- 
and di-methylated peptides after PRMT1 depletion, in line with the enzymatic activity of 
this type-I enzyme, on the other hand a subset of peptides was up-regulated, among them 
mono- and di-methylated were equally distributed. This finding could be partially explained 
with the fact that the global decrease of R di-methylation after the loss of PRMT1 is 
associated with an increase in mono-methylation, as previously described by Dhar and 
colleagues [138]. However, the observed increase of di-methylated peptides cannot be 
explained in light of this evidence and rather suggests the existence of 
compensatory/scavenging effects by other PRMTs. In fact, it has been shown that also 
symmetric di-methylation increases both upon PRMT1 loss [138] and after the inhibition of 
type-I PRMTs [139]. Since our MS-based analysis did not discriminate between 
asymmetric and symmetric di-methylation, we cannot exclude that type-II enzymes are 
compensating the decrease of ADMA, resulting in the up-regulation of some di-methylated 
methyl-peptides.  
To help clarifying this issue, we carried out a SILAC-based proteomic experiment 
overexpressing PRMT1. The methylated peptides identified in this experiment were 
directly compared to those found after PRMT1 depletion, resulting in 42 common methyl-
 90 
 
peptides (Fig. 12B). As expected, 10 methyl-peptides that were not regulated by depletion 
were not affected by overexpression. Five peptides showed the same trend in both KD 
and overexpression experiments, while the remaining were considered genuine PRMT1 
targets; they either displayed an opposite trend between depletion and overexpression 
experiments or they were up-/down-regulated after the PRMT1 KD but not changing when 
the enzyme was overexpressed. A possible explanation for the latter observation is that 
they might be already methylated by the endogenous PRMT1 and thus cannot be further 
modified, resulting in „non-changing‟ ratios. Here, we considered PRMT1 targets also 
methyl-peptides that were not reported in the hmSILAC library, since they were regulated 
consistently after both PRMT1 KD and overexpression.  
When comparing the methylated peptides identified after PRMT1 overexpression with the 
reference library, we observed only a 50% overlap. In fact, 49 methylated-sites, occurring 
on 12 different subunits of the LDC, were not annotated in our library. This could be due 
not only to the fact that these sites might represent false positive identifications (and need 
to be further validated at the MS/MS level) but also to the fact that both endogenous and 
ectopic PRMT1 are present in the cell and they might methylate R residues that are not 
modified at the basal level, thus leading to the identification of new sites. PRMT1, as well 
as other PRMTs, is overexpressed in cancer [50], thus understanding whether the 
overexpression of a certain PRMT leads to an increase of the amount of methylated sites 
on its substrates might be particularly informative, also in a translational perspective.  
The concomitant overexpression and depletion of one or more PRMTs at the same time 
could be particularly useful, for multiple purposes: first, to minimize the 
compensatory/compensation mechanisms among PRMTs; second to avoid the saturation 
effects due to the presence of the endogenous PRMT; third, to assess systematically the 
contribute of each enzyme to the cellular and LDC methyl-proteomes. Recently, the 
Structural Genomics Consortium of the University of Toronto has developed selective 
inhibitors of all type-I enzymes (including PRMT1, 3, 4, 6 and 8), of CARM1 and of all 
type-II enzymes (PRMT5 and PRMT7) [139, 167-169]. We will employ them, alone or in 
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combination, and in association with distinct PRMTs overexpression to dissect more 
systematically the PRMT1 targets in the LDC.  
When we performed methylation analysis to identify PRMT1 targets on the complex, we 
observed ambiguous cases of modification assignments on some of the peptides. This is 
a common issue related to PTMs analysis by mass spectrometry (see Introduction, 
paragraph 2.6), which is particularly relevant in the case of methylation, since there are no 
tailored algorithms to statistically assess the localization of a methyl-site on a peptide, as 
in the case of other PTM such as phosphorylation. The most frequent cases are those of 
peptides for which MaxQuant software assigns a certain methylation type to a specific 
residue with the highest localization probability score, although the MS/MS information is 
not sufficient to confidently localize the detected mass (Fig. 34).  
 
 
 
Fig. 34 Example of ambiguous methylation assignment 
HCD MS/MS spectrum for the peptide 562-GGGYGGDRGGYGGK-576 of TAF15 from the 
proteomic experiment with PRMT1 overexpression (Fig 22B). MaxQuant assigns the 
mass of 28 Da to two mono-methylations on R and K, even if the peptide is not entirely 
fragmented. (Andromeda score = 59.59; localization probability score = 1). 
 
When methylated peptides with ambiguous methylation assignments resulted consistently 
regulated after PRMT1 depletion and overexpression, we decided to consider them as 
substrates of PRMT1 (Fig. 22B). Taking into account these cases, we can define PRMT1 
targets at a „peptides level resolution‟, without precise site localization.  
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After establishing that the modulation of the expression of PRMT1 alters the methylation 
state of the Large Drosha Complex, we explored the possibility that methylation could 
regulate its function, impairing miRNA biogenesis. We initially profiled mature miRNA 
expression upon the depletion of PRMT1 and observed a global massive down-regulation 
of mature miRNAs. Even if the majority of miRNAs were down-regulated by the KD, a 
small subset of miRNAs was not affected or slightly up-regulated. This might reflect the 
fact that depletion of PRMT1 causes methylation changes on several subunits of the 
complex that are known to regulate the Microprocessor in opposite way. In fact, some 
accessory proteins are already recognized as positive regulators of miRNA biogenesis, 
such as DDX5 and DDX17, while others act as negative regulators, such as ILF3 and 
ILF2 (see paragraph 2.2). Therefore, the alteration of methylation induced by PRMT1 KD 
could lead to a subunit-specific and miRNA-specific effect.  
Several components of the LDC are also involved in other cellular processes, such as 
splicing. A specific class of miRNAs, intronic miRNAs, derives from the processing of 
gene introns and requires spliceosomal components for their biogenesis [160]. However, 
we did not observe differences between the two classes when comparing intronic and 
intergenic miRNAs upon PRMT1 depletion, suggesting that they are equally affected. 
Furthermore, PRMT1 depletion does not have a direct impact on how the Microprocessor 
cleaves the pri-miRNAs. This is particularly important since the precise position of Drosha 
cleavage is critical for the generation of mature miRNAs and an error in the cleavage 
could invert the relative stability of the two miRNA strands (5p and 3p), resulting in the 
incorporation of the incorrect strand into the RISC complex [162]. 
However, the significant down-regulation of mature miRNAs observed could be the result 
of the impairment also of other protein complexes that are involved in miRNA pathway 
downstream the LDC, such as Dicer, the Ago proteins and the RISC complex. Thus, we 
focused on the biogenesis step catalyzed by the LDC, which is the processing of the pri- 
to pre-miRNAs, showing that the depletion of PRMT1 leads to a reduction of the precursor 
miRNAs, while the corresponding pri-miRNAs are slightly increased. The accumulation of 
the pri-miRNAs led us to exclude the hypothesis that the observed reduction of pre-
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miRNAs may be a consequence of the effect of PRMT1 KD on the transcription of primary 
transcripts. On the contrary, the accumulation of the pri-miRNAs suggested that there is a 
general blockade of LDC-mediated miRNA processing activity.  
When assessing the subcellular distribution of the pre-miRNAs of miR-15a/16-1 and 17/92 
clusters, we observed that their decrease in the nucleus is followed by an increase in the 
amount of precursors in the cytoplasm. This result led us to speculate that, when the 
processing is affected, the export of the residual pre-miRNAs in the cytoplasm might be 
favored to sustain the production of the mature miRNAs.  
The observation that the expression of Drosha and DGCR8 is not affected by PRMT1 
depletion further suggests that the activity, rather than the amount, of the Microprocessor 
may explain the altered miRNA biogenesis. To specifically assess the enzymatic activity 
of the complex when PRMT1 is depleted, we plan to set up and carry out the 
Microprocessor reporter assay, developed in the group of Gregory [25]. In this assay, the 
pri-miRNA of interest is cloned into the 3‟UTR of the Renilla luciferase gene. The cleavage 
by the Microprocessor is expected to destabilize the Renilla luciferase mRNA and lead to 
decreased Renilla luminescence allowing to measure directly the Microprocessor activity 
on targeted pri-miRNAs.  
To further confirm that the enzymatic activity, rather than the expression, of PRMT1 is 
crucial for the correct processing of miRNAs, we will take advantage of different 
combination of PRMTs inhibitors and we will profile miRNA expression.   
We started to investigate the molecular mechanism linking the PRMT1-regulated arginine 
methylation of the complex to its activity. Methylation is well known to regulate protein 
subcellular localization, protein-protein interactions or protein-RNA interactions. We did 
not observe major changes in the subcellular distribution of several components of the 
LDC in the absence of PRMT1, hence we focused on other mechanisms. The hypothesis 
that methylation might regulate the association of the accessory proteins to the 
Microprocessor is supported by the results on the localization analysis of the methyl-sites 
on the LDC. We found that the methyl-sites regulated by PRMT1 occur mainly in low 
complexity (LC) regions, that are typically involved in both protein-protein and protein-
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RNA interactions [151], or in close proximity of RNA recognition domains (Fig. 20C and 
Fig 22C). Evidence of a role of RNA in mediating interactions of specific subunits with the 
Microprocessor as well as the description of specific protein-protein interactions within the 
LDC were already reported in the literature [17], but at present, a comprehensive analysis 
of how accessory proteins associate to the Microprocessor is still missing. Thus, we set 
up proteomic experiments (described in the Results session, paragraph 5.5.2) that 
combine SILAC with co-IP of the complex to address these open issues.  
If we will observe that the interaction of the accessory subunits with the Microprocessor is 
RNA-mediated, we will further investigate whether the modulation of R-methyl-sites on the 
complex affects their recruitment to the Microprocessor, ultimately impairing miRNA 
biogenesis. In addition, it has been recently reported that R-methylation is able to regulate 
the RNA-binding function of specific RNA-binding proteins [34], thus it will be interesting to 
assess also whether the binding ability of specific accessory proteins to distinct pri-
miRNAs will be affected by PRMT1 depletion.  
Our preliminary data suggest that the modulation of methylation caused by the depletion 
of PRMT1 can influence the interactions of some accessory proteins with the 
Microprocessor. Although the comprehensive proteomic experiment to further confirm this 
result is still on-going, the fact that specific subunits of the complex might be differentially 
recruited to the Microprocessor when their methylation state is altered is intriguing. 
Indeed, this could impair the processing of specific pri-miRNAs, similarly to what has been 
recently described for DDX17 [25]. The authors of this study showed that at high cell 
density DDX17 associates with the Microprocessor and pri-miRNAs, enhancing their 
processing. However, at low cell-density, DDX17 is sequestered from the Microprocessor 
causing a widespread miRNA down-regulation. 
These experiments will provide insights on how the subunits of the LDC interact with the 
Microprocessor and on how PRMT1-mediated R-methylation may regulate the structure of 
the complex, ultimately affecting its activity.  
Indeed, we cannot exclude that other PRMTs may also catalyze the methylation of the 
subunits of the LDC, modulating its function. In fact, while we observed that the KD of 
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PRMT4, PRMT5 and PRMT7 does not significantly impair miRNA processing, at least for 
the subset of miRNAs analyzed, we found that the depletion of PRMT6, which is also a 
type-I enzyme localized in the nucleus, affects the expression of the mature miRNAs 
tested. However, these analyses are still preliminary and further study on both global 
miRNA expression and the methylation state of the complex shall be performed to dissect 
the contribution of each enzyme in the LDC regulation.  
 
Taken together, the results I obtained during my PhD show that the Large Drosha 
Complex contains a large number of high-confidence methylated sites, which are mostly 
catalyzed by PRMT1. Our results also show that the modulation of these R-methylated 
sites has a functional impact on miRNA processing. Hence, although the molecular 
mechanisms linking R-methylation to the altered miRNA biogenesis are still under 
investigation, the results described in this thesis suggest for the first time that R-
methylation plays a key role in the regulation of the LDC activity and therefore in miRNA 
biogenesis.  
Elucidating the molecular mechanisms that underlie altered miRNA biogenesis is essential 
to develop therapeutic strategies to treat aberrant miRNA expression, which is frequently 
associated with pathological states. Thus, studying post translational modification on 
miRNA processing factors might allow the identification of signalling pathways that 
regulate and fine-tune the miRNA machinery. Various inhibitors of protein 
methyltransferases and demethylases have been developed for the so-called epigenetic 
therapy, to revert aberrant methylation patterns on histones. However, these molecules 
may have effects also on non histonic targets, given the emerging awareness that PMTs 
and demethylases act of a much wider panel of substrates. In this scenario, inhibitors of 
PRMTs could be employed to correct the aberrant process influenced by methylation, 
such as miRNA biogenesis. In this perspective, a systematic assessment of the extent of 
protein methylation on the LDC and of its dynamic changes in dependence of distinct 
PRMTs inhibitors can provide crucial information for the implementation of these 
compounds as possible targeted drugs. This is an example of how MS-proteomics can 
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address fundamental questions on a specific cellular mechanism and at the same time, 
offer precious insights towards more translational applications. 
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Appendix 1. Heavy methyl SILAC-based library of the Large Drosha Complex 
methylated sites 
Redundant list of all methylated sites identified through the hmSILAC/co-IP strategy. 
Uniprot protein identifiers (Uniprot ID), protein (Gene), type of methylated residue 
(Residue), site number (Position) and degree of methylation (Degree) and the sequence 
of the modified peptide identified by MS (Modified Sequence) are reported. The 
experiment in which the peptides were identified and the localization of the modified sites 
within each protein (Pfam based analysis) are also listed.  
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Appendix 2. Methylated peptides identified following the depletion of PRMT1 
Redundant list of all methylated peptides identified through the SILAC/co-IP strategy. 
Uniprot protein identifiers (Uniprot ID), protein (Gene), type of methylated residue 
(Residue), site number (Position), degree of methylation (Degree) and the sequence of 
the modified peptide identified by MS (Modified Sequence) are reported. Log2 H/L SILAC 
ratios of modified peptides in the three IPs (DDX5 IP, DGCR8 IP and FUS IP) are 
reported, both in the „forward‟ and „reverse‟ SILAC experiments. Significantly regulated 
peptides that were already reported in the hmSILAC-based library are indicated. 
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Appendix 3. Methylated peptides commonly identified upon PRMT1 depletion and 
overexpression 
List of methylated peptides commonly identified in PRMT1 KD and overexpression 
experiments through the SILAC/co-IP strategy. The sequence of the modified peptide 
identified by MS (Modified Sequence), the averaged log2 H/L SILAC ratios of modified 
peptides identified in DDX5 IP, DGCR8 IP and FUS IP upon KD and overexpression is 
reported (for PRMT1 depletion experiment, ratios from both „forward‟ and „reverse‟ 
experiment are reported). The sites identified within each peptide are indicated.  
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